_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503007782,7/14/2014 20:56:01,,1323093895,7/14/2014 20:55:40,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],TRAUMATIC SHOCK and TRAUMA,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 21:02:47,,1323097610,7/14/2014 21:02:10,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],TRAUMATIC SHOCK TRAUMA,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 21:26:53,,1323108948,7/14/2014 21:26:06,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TRAUMATIC,n/a,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 21:27:21,,1323109211,7/14/2014 21:27:03,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 22:03:33,,1323129982,7/14/2014 22:02:24,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",TRAUMATIC SHOCK TRAUMA induced significant increase circulating microaggregates.,Associated with/ Causes,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 22:03:55,,1323130190,7/14/2014 22:02:13,instagc,1,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],increase,na,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 22:23:43,,1323142885,7/14/2014 22:22:54,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.36,[IS_A],[IS_A],TRAUMA,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 22:35:31,,1323148303,7/14/2014 22:34:15,neodev,1,20929875,USA,MA,Brighton,71.174.178.100,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",after TRAUMATIC SHOCK and that alcohol TRAUMA induced microaggregates.,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/14/2014 23:25:51,,1323170642,7/14/2014 23:24:25,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],alcohol intoxication decreases survival,Drinking alcohol is bad for you and can decrease your life span.,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/15/2014 01:11:44,,1323249414,7/15/2014 01:11:30,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES],[CAUSES],intoxication decreases,dsadw,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/15/2014 01:20:50,,1323255527,7/15/2014 01:20:08,prodege,1,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],indicate,NONE,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/15/2014 02:26:21,,1323294092,7/15/2014 02:25:32,rewardsspot,1,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TRAUMATIC SHOCK TRAUMA,n/a,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/15/2014 03:24:02,,1323316870,7/15/2014 03:23:42,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/15/2014 03:33:44,,1323319746,7/15/2014 03:33:00,elite,1,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,TRAUMATIC SHOCK and that alcohol and TRAUMA,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007782,7/15/2014 03:56:44,,1323330637,7/15/2014 03:55:36,clixsense,1,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],data indicate,N/A,69,69,83,75,-1,RO-cause_of,900439-FS1,The data indicate that alcohol intoxication decreases survival after TRAUMATIC SHOCK and that alcohol and TRAUMA induced a significant increase in circulating microaggregates.,TRAUMATIC SHOCK,TRAUMA
503007783,7/14/2014 20:36:24,,1323083858,7/14/2014 20:35:30,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],is,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/14/2014 21:05:27,,1323099016,7/14/2014 21:04:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],is one of the most frequent COMPLICATIONS OF PREGNANCY,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/14/2014 21:23:36,,1323107235,7/14/2014 21:23:20,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],COMPLICATIONS,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/14/2014 21:47:47,,1323122697,7/14/2014 21:47:10,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],one of the most frequent,[CAUSES],41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/14/2014 21:50:19,,1323124053,7/14/2014 21:50:02,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],is one of the most frequent,N/a,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/14/2014 22:24:23,,1323143255,7/14/2014 22:23:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[IS_A],[IS_A],is,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/14/2014 23:35:47,,1323175872,7/14/2014 23:35:22,superrewards,1,23067591,USA,VA,Lynchburg,76.104.12.135,[SIDE_EFFECT],[SIDE_EFFECT],PREECLAMPSIA frequent COMPLICATIONS OF PREGNANCY,na,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 00:39:06,,1323224203,7/15/2014 00:38:31,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],PREECLAMPSIA is one of COMPLICATIONS OF PREGNANCY,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 02:03:35,,1323283752,7/15/2014 02:02:43,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PREECLAMPSIA COMPLICATIONS OF PREGNANCY,n/a,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 03:58:30,,1323331536,7/15/2014 03:57:55,elite,1.0,27788262,USA,"","",172.129.7.231,[IS_A],[IS_A],is one of the most frequent,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 04:12:19,,1323338248,7/15/2014 04:09:43,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",PREECLAMPSIA one most frequent COMPLICATIONS OF PREGNANCY,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 05:02:49,,1323357702,7/15/2014 05:02:04,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],one of the most frequent COMPLICATIONS,n/a,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 05:34:54,,1323368460,7/15/2014 05:33:57,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION],[MANIFESTATION],most frequent COMPLICATIONS,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 05:37:53,,1323369191,7/15/2014 05:37:29,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],one of the most frequent,N/A,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007783,7/15/2014 05:56:56,,1323375017,7/15/2014 05:56:15,clixsense,1,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],is one of the most frequent COMPLICATIONS OF PREGNANCY,one of the most frequent COMPLICATIONS OF PREGNANCY,41,0,66,12,-1,RO-disease_has_finding,901807-FS1,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503007784,7/14/2014 20:40:45,,1323086126,7/14/2014 20:40:37,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],followed,n/a,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/14/2014 20:56:43,,1323094264,7/14/2014 20:56:09,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for ST elevation,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/14/2014 21:14:17,,1323103089,7/14/2014 21:13:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],is recommended for ST elevation MYOCARDIAL INFARCTION,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/14/2014 21:17:06,,1323104396,7/14/2014 21:16:39,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],recommended with,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/14/2014 21:49:30,,1323123718,7/14/2014 21:48:54,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],for ST elevation MYOCARDIAL INFARCTION,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/14/2014 22:20:45,,1323140844,7/14/2014 22:18:38,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[TREATS],[TREATS],recommended with ALTEPLASE for MYOCARDIAL INFARCTION,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/14/2014 22:25:35,,1323143939,7/14/2014 22:24:40,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],recommended ALTEPLASE for ST elevation MYOCARDIAL INFARCTION,Treats,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 00:29:01,,1323215660,7/15/2014 00:28:14,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 01:12:51,,1323250084,7/15/2014 01:11:58,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",recommended for,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 01:26:08,,1323259171,7/15/2014 01:25:40,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],recommended,NONE,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 03:28:16,,1323318064,7/15/2014 03:27:53,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],ALTEPLASE for MYOCARDIAL INFARCTION,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 03:52:44,,1323328549,7/15/2014 03:50:37,elite,1.0,27788262,USA,"","",172.129.7.231,[TREATS],[TREATS],is recommended for,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 05:03:47,,1323357988,7/15/2014 05:03:21,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],elevation,na,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 05:17:04,,1323362528,7/15/2014 05:16:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],is recommended with,N/A,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007784,7/15/2014 06:13:07,,1323379852,7/15/2014 06:12:27,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[TREATS],[TREATS],elevation,is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION,153,126,173,135,1,RO-may_treat,908164-FS1,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
503007785,7/14/2014 20:56:05,,1323093941,7/14/2014 20:54:37,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[SYMPTOM] [ASSOCIATED_WITH] [PART_OF] [IS_A],"[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",oral administration of CITRATE useful in the management RENAL STONE DISEASE.,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 21:27:28,,1323109316,7/14/2014 21:27:13,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],management,n/a,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 21:53:54,,1323125628,7/14/2014 21:53:09,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",has been suggested to be clinically useful in the management of,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 22:01:27,,1323128860,7/14/2014 22:00:46,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],CITRATE been clinically useful management RENAL STONE DISEASE.,treats,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 22:32:13,,1323146964,7/14/2014 22:31:36,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[TREATS],[TREATS],management of,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 22:34:57,,1323148079,7/14/2014 22:34:12,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],clinically useful in the management,na,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 22:44:00,,1323151493,7/14/2014 22:41:25,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],clinically useful in the management of,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/14/2014 23:34:53,,1323175267,7/14/2014 23:34:31,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[TREATS],[TREATS],recently oral administration of CITRATE has been clinically useful in management of RENAL STONE DISEASE.,naa,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 00:35:44,,1323221244,7/15/2014 00:34:43,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",CITRATE be clinically useful of RENAL STONE DISEASE.,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 01:59:18,,1323280963,7/15/2014 01:58:45,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],management,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 02:28:28,,1323294907,7/15/2014 02:27:54,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],CITRATE RENAL STONE DISEASE.,n/a,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 02:46:36,,1323302248,7/15/2014 02:46:12,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],management,not applicable,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 03:20:33,,1323315709,7/15/2014 03:20:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],CITRATE useful in RENAL DISEASE.,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 03:55:41,,1323330082,7/15/2014 03:54:51,elite,1.0,27788262,USA,"","",172.129.7.231,[TREATS],[TREATS],has been suggested to be clinically useful in the management of,N/A,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007785,7/15/2014 05:07:32,,1323359208,7/15/2014 05:07:03,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],suggested to be clinically useful in the management,n/a,190,118,208,125,1,RO-may_prevent,907076-FS1,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
503007786,7/14/2014 20:43:14,,1323087290,7/14/2014 20:42:40,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],labeled for treatment of,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/14/2014 20:44:06,,1323087765,7/14/2014 20:43:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],treatment,n/a,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/14/2014 21:07:44,,1323100128,7/14/2014 21:07:10,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/14/2014 21:27:36,,1323109350,7/14/2014 21:27:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/14/2014 21:27:40,,1323109395,7/14/2014 21:27:29,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/14/2014 21:36:15,,1323114151,7/14/2014 21:36:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PIMECROLIMUS ATOPIC DERMATITIS,n/a,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/14/2014 21:45:20,,1323120909,7/14/2014 21:45:00,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],treatment,na,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 00:36:18,,1323221840,7/15/2014 00:35:45,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],PIMECROLIMUS for treatment of ATOPIC DERMATITIS,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 01:09:19,,1323247663,7/15/2014 01:08:05,prodege,1,2145087,USA,WV,Wheeling,71.199.112.204,[TREATS],[TREATS],for treatment of,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 01:13:30,,1323250638,7/15/2014 01:12:53,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 02:36:59,,1323298294,7/15/2014 02:36:31,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],PIMECROLIMUS ATOPIC DERMATITIS,n/a,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 04:51:04,,1323353762,7/15/2014 04:50:07,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],topical non steroidal drug labeled for treatment,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 05:02:03,,1323357503,7/15/2014 05:01:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],for treatment of,n/a,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 05:07:04,,1323359044,7/15/2014 05:06:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treatment of,N/A,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007786,7/15/2014 05:17:17,,1323362613,7/15/2014 05:16:54,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treatment,na,96,0,112,12,1,RO-may_treat,908166-FS1,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
503007787,7/14/2014 20:39:30,,1323085541,7/14/2014 20:39:22,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],NERVOUS SYSTEM,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/14/2014 21:07:38,,1323100100,7/14/2014 21:05:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],hereditary disorders affecting the,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/14/2014 21:54:04,,1323125678,7/14/2014 21:51:45,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],affecting the,n/a,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/14/2014 21:54:47,,1323125965,7/14/2014 21:54:31,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],affecting the NERVOUS SYSTEM,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/14/2014 22:20:58,,1323141014,7/14/2014 22:20:07,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],NEUROFIBROMATOSIS affecting NERVOUS SYSTEM,Location,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/14/2014 22:28:03,,1323145240,7/14/2014 22:25:09,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[SYMPTOM] [MANIFESTATION] [CAUSES],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",NEUROFIBROMATOSIS hereditary disorders affecting the NERVOUS SYSTEM,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/14/2014 23:43:50,,1323181317,7/14/2014 23:43:36,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[LOCATION],[LOCATION],NEUROFIBROMATOSIS disorders affecting the NERVOUS SYSTEM,na,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 00:33:28,,1323219423,7/15/2014 00:32:17,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],NEUROFIBROMATOSIS disorders affecting the NERVOUS SYSTEM,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 02:35:47,,1323297778,7/15/2014 02:35:10,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],NEUROFIBROMATOSIS NERVOUS SYSTEM,n/a,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 03:18:00,,1323314960,7/15/2014 03:17:44,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[LOCATION],[LOCATION],affecting,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 03:28:19,,1323318072,7/15/2014 03:26:22,elite,1.0,27788262,USA,"","",172.129.7.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],affecting,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 04:04:48,,1323334449,7/15/2014 04:04:17,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],three hereditary disorders,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 04:35:46,,1323349233,7/15/2014 04:35:10,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",hereditary disorders,N/A,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 05:06:34,,1323358843,7/15/2014 05:06:07,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],affecting,na,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007787,7/15/2014 05:13:13,,1323361142,7/15/2014 05:12:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],NEUROFIBROMATOSIS hereditary disorders affecting the,n/a,108,0,121,17,1,RO-has_finding_site,905210-FS1,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
503007788,7/14/2014 20:41:37,,1323086552,7/14/2014 20:41:29,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],remission,n/a,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 20:49:51,,1323090737,7/14/2014 20:49:35,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 21:04:14,,1323098460,7/14/2014 21:03:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for maintenance of remission in,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 21:09:36,,1323100952,7/14/2014 21:09:11,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CONTRAINDICATES],[CONTRAINDICATES],remission,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 21:11:53,,1323102067,7/14/2014 21:11:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],for maintenance of remission in,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 22:31:31,,1323146634,7/14/2014 22:30:46,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[TREATS],[TREATS],maintenance of remission,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 22:33:27,,1323147426,7/14/2014 22:32:53,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/14/2014 23:19:46,,1323167862,7/14/2014 23:19:06,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,Sorry i am a bit confused as to where this falls under,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 01:14:44,,1323251429,7/15/2014 01:14:18,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],maintenance,none,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 01:20:53,,1323255549,7/15/2014 01:20:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],maintenance of remission,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 01:53:42,,1323277244,7/15/2014 01:53:07,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],MESALAMINE ULCERATIVE COLITIS,n/a,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 03:50:35,,1323327566,7/15/2014 03:49:31,elite,1.0,27788262,USA,"","",172.129.7.231,[PREVENTS],[PREVENTS],for maintenance of remission in,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 04:20:55,,1323342760,7/15/2014 04:20:00,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[TREATS],[TREATS],maintenance of remission,N/A,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 05:01:44,,1323357469,7/15/2014 05:01:20,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],maintenance of remission,n/a,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007788,7/15/2014 05:12:45,,1323360943,7/15/2014 05:12:18,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],maintenance,na,85,42,102,52,1,RO-may_treat,907599-FS1,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
503007789,7/14/2014 20:38:47,,1323085152,7/14/2014 20:38:21,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],amplified with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY,N/A,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 20:42:54,,1323087110,7/14/2014 20:42:47,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"leukoencephalopathy,",n/a,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 21:20:19,,1323105764,7/14/2014 21:19:50,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],with and without,N/A,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 21:34:43,,1323113246,7/14/2014 21:34:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],amplified,n/a,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 21:41:59,,1323118206,7/14/2014 21:40:43,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[NONE],[NONE],N/A,MULTIFOCAL LEUKOENCEPHALOPATHY has no relation to first word. Testing is done with patients who both have it and don't. It is just an extra so no relation.,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 21:48:15,,1323122968,7/14/2014 21:47:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",ISOLATES amplified,n/a,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 22:23:30,,1323142737,7/14/2014 22:22:44,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],with and without,na,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/14/2014 22:53:47,,1323155699,7/14/2014 22:52:23,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],with and without,N/A,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 01:11:57,,1323249572,7/15/2014 01:11:15,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],verify the possibility of,N/A,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 02:37:53,,1323298695,7/15/2014 02:37:02,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],JC VIRUS ISOLATES AIDS MULTIFOCAL LEUKOENCEPHALOPATHY,n/a,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 03:38:37,,1323321926,7/15/2014 03:37:56,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 05:08:30,,1323359553,7/15/2014 05:07:16,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],etiology of,N/A,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 05:13:45,,1323361306,7/15/2014 05:13:16,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],progressive,na,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 05:30:20,,1323366923,7/15/2014 05:29:55,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with and without,N/A,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007789,7/15/2014 06:13:53,,1323380090,7/15/2014 06:13:08,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],amplified,we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY,149,225,165,255,1,RO-has_causative_agent,903673-FS1,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
503007790,7/14/2014 21:19:37,,1323105441,7/14/2014 21:19:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],causes,N/A,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/14/2014 21:29:59,,1323110731,7/14/2014 21:29:03,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],causes,n/a,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/14/2014 21:38:35,,1323115614,7/14/2014 21:37:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],that causes,[CAUSES],0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/14/2014 21:55:41,,1323126231,7/14/2014 21:53:21,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],causes,na,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/14/2014 22:45:47,,1323152137,7/14/2014 22:45:21,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[IS_A] [CAUSES],"[CAUSES]
[IS_A]",EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,N/A,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 01:10:22,,1323248475,7/15/2014 01:10:02,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[IS_A] [CONTRAINDICATES],"[CONTRAINDICATES]
[IS_A]",herpesvirus,dawdw,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 01:54:51,,1323277962,7/15/2014 01:53:47,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],EPSTEIN BARR VIRUS INFECTIOUS MONONUCLEOSIS,n/a,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 03:07:47,,1323311298,7/15/2014 03:07:11,clixsense,1.0,14466721,CAN,ON,Hamilton,216.209.129.175,[CAUSES],[CAUSES],is a herpesvirus that causes,N/A,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 05:05:23,,1323358512,7/15/2014 05:04:42,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],causes,N/A,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 05:17:41,,1323362748,7/15/2014 05:17:18,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],causes,na,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 05:28:41,,1323366386,7/15/2014 05:28:25,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],causes,N/A,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 06:16:12,,1323380667,7/15/2014 06:15:46,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],causes,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 06:34:48,,1323386029,7/15/2014 06:34:25,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],causes,n/a,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 06:39:50,,1323387568,7/15/2014 06:39:19,neodev,1,17111650,USA,PA,Millersburg,174.59.14.30,[CAUSES],[CAUSES],that causes,N/A,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007790,7/15/2014 07:26:58,,1323407482,7/15/2014 07:26:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],causes,Na,0,48,17,72,1,RO-has_causative_agent,903553-FS1,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
503007791,7/14/2014 20:59:11,,1323095763,7/14/2014 20:58:56,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],restoration,n/a,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 21:16:06,,1323103986,7/14/2014 21:15:43,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],(in,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 21:26:44,,1323108904,7/14/2014 21:26:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PART_OF],[PART_OF],(in,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 21:50:39,,1323124221,7/14/2014 21:50:20,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],(in,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 22:07:10,,1323132210,7/14/2014 22:06:13,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],part of the body,na,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 22:16:01,,1323137727,7/14/2014 22:14:47,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",BRAIN (in STROKE,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 22:31:31,,1323146637,7/14/2014 22:30:41,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[PART_OF] [LOCATION],"[LOCATION]
[PART_OF]",restoration of blood flow to a part of the body the heart muscle BRAIN,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/14/2014 22:52:22,,1323154987,7/14/2014 22:51:59,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],(in,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 01:10:52,,1323248805,7/15/2014 01:10:11,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],or,none,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 01:55:51,,1323278574,7/15/2014 01:55:33,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],(in,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 02:07:57,,1323285987,7/15/2014 02:07:12,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRAIN STROKE,n/a,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 02:18:46,,1323291027,7/15/2014 02:17:51,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRAIN STROKE,n/a,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 05:06:05,,1323358701,7/15/2014 05:04:43,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",(in,na,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 05:27:34,,1323365975,7/15/2014 05:26:40,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],restoration of blood flow,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007791,7/15/2014 05:32:54,,1323367749,7/15/2014 05:32:36,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],(in,N/A,156,166,160,172,1,RO-disease_has_primary_anatomic_site,902102-FS1,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
503007792,7/14/2014 20:49:28,,1323090445,7/14/2014 20:49:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM),N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/14/2014 21:52:59,,1323125259,7/14/2014 21:52:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROTEIN DEFICIT and PROTEIN CALORIE MALNUTRITION were estimated,associated with,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/14/2014 22:22:25,,1323142010,7/14/2014 22:21:19,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],n/a,No direct relationship is given.,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/14/2014 22:32:53,,1323147186,7/14/2014 22:32:19,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[OTHER],[OTHER],PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/14/2014 22:56:40,,1323156807,7/14/2014 22:56:17,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/14/2014 23:13:06,,1323164349,7/14/2014 23:11:51,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],and,n/a,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/14/2014 23:34:32,,1323175031,7/14/2014 23:33:26,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],PROTEIN DEFICIT and PROTEIN CALORIE MALNUTRITION,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 01:06:55,,1323246050,7/15/2014 01:06:34,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES] [CONTRAINDICATES] [ASSOCIATED_WITH] [LOCATION],"[CAUSES]
[LOCATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]",PROTEIN CALORIE,dsas,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 01:42:47,,1323270027,7/15/2014 01:40:09,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated between control,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 02:17:48,,1323290542,7/15/2014 02:17:26,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROTEIN DEFICIT (PD) PROTEIN CALORIE MALNUTRITION (PCM),n/a,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 04:39:55,,1323350479,7/15/2014 04:38:03,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],and,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 05:12:17,,1323360786,7/15/2014 05:10:43,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],and,na,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 05:15:53,,1323362078,7/15/2014 05:15:31,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 05:29:54,,1323366840,7/15/2014 05:29:32,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007792,7/15/2014 06:57:51,,1323393096,7/15/2014 06:56:41,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM],[SYMPTOM],and,n/a,25,0,52,20,-1,RO-cause_of,900289-FS1,"PROTEIN DEFICIT (PD) and PROTEIN CALORIE MALNUTRITION (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein fed animals, respectively.",PROTEIN CALORIE MALNUTRITION,PROTEIN DEFICIT (PD)
503007793,7/14/2014 20:41:14,,1323086380,7/14/2014 20:41:06,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],COMPLICATION,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 20:45:53,,1323088636,7/14/2014 20:45:39,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],PREECLAMPSIA is a PREGNANCY COMPLICATION,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 20:59:32,,1323095947,7/14/2014 20:57:40,clixsense,1.0,15189335,GBR,H9,London,188.29.165.118,[SYMPTOM],[SYMPTOM],is a,Na,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 21:08:06,,1323100326,7/14/2014 21:07:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],is a,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 21:12:23,,1323102302,7/14/2014 21:11:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],is a,n/a,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 21:15:17,,1323103585,7/14/2014 21:14:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],is a,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 21:21:29,,1323106212,7/14/2014 21:21:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],is a,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 21:47:57,,1323122795,7/14/2014 21:47:40,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],is a,N/a,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 22:19:12,,1323139817,7/14/2014 22:18:30,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],PREECLAMPSIA is a PREGNANCY COMPLICATION,manifestation,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 22:30:33,,1323146204,7/14/2014 22:28:05,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[ASSOCIATED_WITH] [MANIFESTATION] [SIDE_EFFECT],"[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",PREECLAMPSIA is a PREGNANCY COMPLICATION caused by compounds from hypoxic tissues.,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 22:47:16,,1323152737,7/14/2014 22:47:03,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],is a,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/14/2014 23:03:54,,1323160735,7/14/2014 23:03:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",PREECLAMPSIA is PREGNANCY COMPLICATION,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/15/2014 01:23:38,,1323257505,7/15/2014 01:23:00,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,NONE,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/15/2014 02:02:01,,1323282911,7/15/2014 02:00:54,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PREECLAMPSIA PREGNANCY COMPLICATION,n/a,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007793,7/15/2014 03:21:58,,1323316215,7/15/2014 03:21:30,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],PREECLAMPSIA is PREGNANCY COMPLICATION,N/A,18,0,39,12,-1,RO-disease_has_finding,901534-FS1,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
503007794,7/14/2014 20:45:00,,1323088204,7/14/2014 20:44:41,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],(moderate CIS),N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/14/2014 20:48:21,,1323089847,7/14/2014 20:47:50,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],LESION DYSPLASIA,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/14/2014 21:16:42,,1323104232,7/14/2014 21:16:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LESION dysplasia,",N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/14/2014 21:24:14,,1323107534,7/14/2014 21:23:39,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],favor,n/a,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/14/2014 21:30:15,,1323110863,7/14/2014 21:29:39,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(LSIL) DYSPLASIA,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/14/2014 21:55:42,,1323126235,7/14/2014 21:54:32,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],"LESION (LSIL) DYSPLASIA CIN 2, CIN 3, CIS)",symptom,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/14/2014 22:50:05,,1323153927,7/14/2014 22:49:01,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],Low grade squamous intraepithelial (moderate to severe,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 01:19:17,,1323254556,7/15/2014 01:18:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],consistent with,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 01:43:05,,1323270209,7/15/2014 01:42:00,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",features suspicious of invasion),N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 02:05:35,,1323284674,7/15/2014 02:04:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LESION (LSIL) DYSPLASIA,n/a,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 03:13:23,,1323313520,7/15/2014 03:12:20,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],LESION (LSIL) severe DYSPLASIA,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 03:21:17,,1323315946,7/15/2014 03:20:50,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[LOCATION],[LOCATION],intraepithelial,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 04:30:34,,1323347397,7/15/2014 04:29:29,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[MANIFESTATION],[MANIFESTATION],"changes consistent with mild dysplasia,",N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 04:38:02,,1323349911,7/15/2014 04:36:14,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[ASSOCIATED_WITH],[ASSOCIATED_WITH],consistent with,N/A,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007794,7/15/2014 05:07:39,,1323359295,7/15/2014 05:07:02,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],(indicate,na,181,35,189,48,-1,RO-disease_has_finding,901899-FS1,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
503007795,7/14/2014 20:41:29,,1323086488,7/14/2014 20:41:20,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],endpoints,n/a,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 20:42:37,,1323086968,7/14/2014 20:41:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],offer new endpoints for an early identification of,N/A,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 21:21:53,,1323106394,7/14/2014 21:20:38,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],offer new endpoints,n/a,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 21:25:45,,1323108318,7/14/2014 21:25:31,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],and,n/a,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 21:31:48,,1323111736,7/14/2014 21:30:01,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],differences between,n/a,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 21:49:19,,1323123584,7/14/2014 21:48:30,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",offer new endpoints for,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 21:59:39,,1323127954,7/14/2014 21:57:44,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],identification of,n/a,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 22:32:13,,1323146963,7/14/2014 22:30:34,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[SIDE_EFFECT] [CAUSES],"[CAUSES]
[SIDE_EFFECT]",COMPLICATED PREGNANCIES early identification of PREECLAMPSIA,N/A,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/14/2014 23:33:38,,1323174460,7/14/2014 23:33:03,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[SIDE_EFFECT],[SIDE_EFFECT],and COMPLICATED PREGNANCIES early identification of gestational hypertension and PREECLAMPSIA,na,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/15/2014 00:44:20,,1323228263,7/15/2014 00:43:59,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],COMPLICATED PREGNANCIES early identification of PREECLAMPSIA,N/A,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/15/2014 03:29:33,,1323318347,7/15/2014 03:28:58,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],COMPLICATED PREGNANCIES early identification PREECLAMPSIA,N/A,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/15/2014 03:50:42,,1323327629,7/15/2014 03:49:18,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],early identification,N/A,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/15/2014 05:19:07,,1323363189,7/15/2014 05:18:13,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CONTRAINDICATES],[CONTRAINDICATES],differences between,N/A,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/15/2014 06:02:57,,1323377045,7/15/2014 06:01:34,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],offer new endpoints,offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007795,7/15/2014 06:04:19,,1323377425,7/15/2014 06:01:57,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],offer new endpoints for an early identification,Did not,42,146,64,158,-1,RO-disease_has_finding,901933-FS1,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
503007796,7/14/2014 20:47:12,,1323089304,7/14/2014 20:46:32,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[MANIFESTATION],[MANIFESTATION],multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 20:54:36,,1323093192,7/14/2014 20:53:04,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH] [PART_OF] [IS_A],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",BONE METASTASES the METASTATIC LESION OF THE SKULL,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 21:26:03,,1323108547,7/14/2014 21:25:46,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],the,n/a,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 21:47:17,,1323122392,7/14/2014 21:45:43,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[IS_A],[IS_A],multiple BONE METASTASES the METASTATIC LESION OF THE SKULL,na,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 21:52:45,,1323125146,7/14/2014 21:52:12,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[SYMPTOM],[SYMPTOM],was clearly demonstrated,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 22:28:59,,1323145542,7/14/2014 22:27:49,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[LOCATION],[LOCATION],the METASTATIC LESION OF THE SKULL was clearly demonstrated,na,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 22:35:36,,1323148332,7/14/2014 22:35:08,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION],[LOCATION],the METASTATIC LESION OF THE SKULL,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/14/2014 22:50:04,,1323153907,7/14/2014 22:49:42,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],the,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 01:17:46,,1323253535,7/15/2014 01:17:17,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],demonstrated,NONE,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 01:21:23,,1323255898,7/15/2014 01:19:40,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",was clearly demonstrated,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 02:47:35,,1323302754,7/15/2014 02:46:37,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],n/a,I do not see any words that express a relation.,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 03:24:14,,1323316937,7/15/2014 03:23:28,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF],[PART_OF],BONE METASTASES METASTATIC LESION OF THE SKULL,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 03:45:48,,1323325233,7/15/2014 03:45:08,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,BONE METASTASES the METASTATIC LESION OF THE SKULL,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 04:24:12,,1323344460,7/15/2014 04:22:43,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[SYMPTOM] [MANIFESTATION] [OTHER],"[SYMPTOM]
[MANIFESTATION]
[OTHER]",case of,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007796,7/15/2014 05:25:25,,1323365304,7/15/2014 05:24:20,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],clearly demonstrated,N/A,44,24,73,39,1,RO-disease_has_finding,901939-FS1,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
503007797,7/14/2014 20:39:22,,1323085461,7/14/2014 20:39:11,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],a model of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/14/2014 20:39:52,,1323085727,7/14/2014 20:39:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],as a consequence of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/14/2014 21:07:17,,1323099949,7/14/2014 21:06:55,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a model of,n/a,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/14/2014 21:44:16,,1323119968,7/14/2014 21:42:53,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],a model of,N/a,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/14/2014 21:46:51,,1323122158,7/14/2014 21:46:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THIAMINE WERNICKE'S ENCEPHALOPATHY,n/a,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/14/2014 22:22:26,,1323142022,7/14/2014 22:21:38,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],consequence of,na,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/14/2014 23:43:20,,1323180845,7/14/2014 23:42:39,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],n/a,n/a,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 01:10:10,,1323248317,7/15/2014 01:09:44,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],consequence,none,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 04:22:36,,1323343603,7/15/2014 04:21:49,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[IS_A],[IS_A],a model of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 04:34:58,,1323348985,7/15/2014 04:33:42,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],a model of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 05:09:42,,1323359958,7/15/2014 05:08:54,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],a model of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 05:20:13,,1323363622,7/15/2014 05:19:08,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",consequence elevation,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 05:31:34,,1323367378,7/15/2014 05:31:03,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a model of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 06:15:57,,1323380609,7/15/2014 06:15:06,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM],[SYMPTOM],model of,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007797,7/15/2014 06:20:24,,1323381826,7/15/2014 06:19:40,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[NONE],[NONE],N/A,N/A,91,42,115,73,1,RO-may_treat,908170-FS1,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
503007798,7/14/2014 20:40:28,,1323086015,7/14/2014 20:39:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],preferred therapy for,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/14/2014 21:02:09,,1323097270,7/14/2014 21:01:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],was the preferred therapy for,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/14/2014 21:09:09,,1323100763,7/14/2014 21:08:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],preferred therapy,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/14/2014 21:19:27,,1323105375,7/14/2014 21:19:11,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],therapy,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/14/2014 21:24:20,,1323107587,7/14/2014 21:23:59,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],therapy,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/14/2014 22:02:40,,1323129459,7/14/2014 22:01:46,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],was the preferred therapy for,n/a,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/14/2014 23:38:57,,1323177776,7/14/2014 23:36:28,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[TREATS],[TREATS],URSODEOXYCHOLIC ACID was preferred therapy for GALLSTONE DISSOLUTION,na,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 00:40:30,,1323225350,7/15/2014 00:39:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],preferred therapy,n/a,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 00:42:59,,1323227235,7/15/2014 00:42:38,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",URSODEOXYCHOLIC ACID was preferred therapy for GALLSTONE DISSOLUTION,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 01:11:26,,1323249214,7/15/2014 01:11:11,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[PREVENTS] [CONTRAINDICATES],"[PREVENTS]
[CONTRAINDICATES]",concluded that the,dasdw,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 01:52:32,,1323276529,7/15/2014 01:51:36,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],therapy,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 01:56:55,,1323279237,7/15/2014 01:56:17,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],URSODEOXYCHOLIC ACID GALLSTONE DISSOLUTION,n/a,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 02:34:41,,1323297397,7/15/2014 02:34:03,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],URSODEOXYCHOLIC ACID GALLSTONE DISSOLUTION,n/a,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 03:17:11,,1323314663,7/15/2014 03:16:34,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],therapy,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007798,7/15/2014 03:21:29,,1323316029,7/15/2014 03:21:06,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],URSODEOXYCHOLIC ACID therapy GALLSTONE DISSOLUTION,N/A,123,72,143,92,1,RO-may_treat,908173-FS1,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
503007799,7/14/2014 20:39:07,,1323085331,7/14/2014 20:38:48,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],after BUMETANIDE,N/A,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 20:41:18,,1323086409,7/14/2014 20:41:11,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],EDEMA,n/a,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 20:55:39,,1323093681,7/14/2014 20:55:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],no EDEMA 24 h after BUMETANIDE,N/A,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 21:15:22,,1323103621,7/14/2014 21:15:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],after,N/A,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 21:15:58,,1323103914,7/14/2014 21:15:15,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],24 h after,N/A,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 21:49:49,,1323123855,7/14/2014 21:49:31,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],no EDEMA 24 h after BUMETANIDE,N/A,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 22:00:45,,1323128508,7/14/2014 21:59:31,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",marked edema 1 hr and no EDEMA 24 after BUMETANIDE,diagnose by test or drug/ manifestation,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 22:40:46,,1323150180,7/14/2014 22:40:15,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/14/2014 23:32:14,,1323173721,7/14/2014 23:31:42,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[OTHER] [TREATS],"[TREATS]
[OTHER]",no EDEMA 24 h after BUMETANIDE,na,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/15/2014 00:43:19,,1323227453,7/15/2014 00:42:49,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],after,n/a,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/15/2014 01:09:18,,1323247653,7/15/2014 01:09:03,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[PREVENTS],[PREVENTS],"min,",dsadw,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/15/2014 01:55:35,,1323278340,7/15/2014 01:54:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],EDEMA BUMETANIDE,n/a,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/15/2014 02:36:28,,1323298086,7/15/2014 02:35:49,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],EDEMA BUMETANIDE,n/a,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/15/2014 03:37:54,,1323321595,7/15/2014 03:37:23,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,EDEMA 24 h after BUMETANIDE,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007799,7/15/2014 05:10:00,,1323360083,7/15/2014 05:09:34,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],after,na,70,87,74,97,1,RO-may_treat,908056-FS1,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
503007800,7/14/2014 20:46:25,,1323088946,7/14/2014 20:45:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was,N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/14/2014 20:47:48,,1323089568,7/14/2014 20:47:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU,N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/14/2014 21:04:29,,1323098608,7/14/2014 21:03:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/14/2014 21:05:39,,1323099113,7/14/2014 21:04:54,clixsense,1.0,15189335,GBR,H9,London,188.29.164.19,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,Na,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/14/2014 21:33:20,,1323112505,7/14/2014 21:32:40,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],equally,n/a,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/14/2014 21:35:39,,1323113821,7/14/2014 21:35:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA or SQUAMOUS CARCINOMA,n/a,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 01:12:20,,1323249780,7/15/2014 01:11:38,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],"all malignancies,",none,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 01:53:24,,1323277051,7/15/2014 01:53:07,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],or,N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 02:10:19,,1323287179,7/15/2014 02:09:47,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA SQUAMOUS CARCINOMA IN SITU,n/a,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 04:43:39,,1323351600,7/15/2014 04:42:25,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[IS_A],[IS_A],"four categories, or",N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 05:05:58,,1323358645,7/15/2014 05:05:35,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA or SQUAMOUS CARCINOMA,n/a,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 05:29:35,,1323366727,7/15/2014 05:28:34,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[LOCATION],[LOCATION],"all malignancies,",N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 06:20:41,,1323381894,7/15/2014 06:20:11,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 07:26:06,,1323407206,7/15/2014 07:25:51,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[IS_A],[IS_A],or,Na,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007800,7/15/2014 07:30:39,,1323408865,7/15/2014 07:29:16,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],or,N/A,112,132,127,158,-1,RO-disease_has_finding,901780-FS1,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) SEVERE DYSPLASIA or SQUAMOUS CARCINOMA IN SITU and (4) all malignancies, was almost equally informative.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
503007801,7/14/2014 21:13:54,,1323102900,7/14/2014 21:13:38,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATOMA HEPATOMA,N/A,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/14/2014 21:42:25,,1323118558,7/14/2014 21:41:33,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]",rat hepatoma 27 reacted with,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT],266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/14/2014 21:58:38,,1323127421,7/14/2014 21:57:48,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA,is a,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/14/2014 22:35:07,,1323148154,7/14/2014 22:33:28,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/14/2014 22:55:05,,1323156157,7/14/2014 22:54:43,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],and,N/A,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 00:42:48,,1323227091,7/15/2014 00:41:42,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],and,two different hepatomas,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 04:06:04,,1323335081,7/15/2014 04:04:51,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reaction,N/A,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 04:28:29,,1323346582,7/15/2014 04:26:18,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",Zajdela's ascites,N/A,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 05:35:11,,1323368516,7/15/2014 05:32:06,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[NONE],[NONE],N/A,[NONE],266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 06:33:23,,1323385674,7/15/2014 06:31:49,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,no relation found,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 07:26:27,,1323407284,7/15/2014 07:26:08,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 07:33:10,,1323409841,7/15/2014 07:32:37,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Unrelated conditions.,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 07:49:45,,1323415554,7/15/2014 07:48:45,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,both examples of the same disease,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 08:33:06,,1323432505,7/15/2014 08:31:20,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],and,N/A,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007801,7/15/2014 08:52:38,,1323439401,7/15/2014 08:51:58,prodege,1.0,21891314,AUS,07,Glen Iris,58.6.248.249,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,266,291,285,317,-1,RO-disease_may_have_finding,902597-FS1,"Rabbit antiserum against alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's RAT ASCITES HEPATOMA and MOUSE ASCITES HEPATOMA 22A while the reaction with non liver tumors  rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",RAT ASCITES HEPATOMA,MOUSE ASCITES HEPATOMA 22A
503007802,7/14/2014 20:49:03,,1323090233,7/14/2014 20:48:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION were studied.,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/14/2014 20:59:34,,1323095967,7/14/2014 20:58:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],POISONING,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/14/2014 21:19:19,,1323105302,7/14/2014 21:18:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlations between,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/14/2014 21:19:19,,1323105314,7/14/2014 21:18:40,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],correlations,n/a,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/14/2014 21:25:25,,1323108114,7/14/2014 21:25:02,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlations between,n/a,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/14/2014 21:49:45,,1323123816,7/14/2014 21:49:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SUICIDAL DIGOXIN POISONING SERUM DIGOXIN CONCENTRATION,n/a,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/14/2014 22:25:07,,1323143656,7/14/2014 22:23:13,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",patients with SUICIDAL DIGOXIN POISONING correlations between SERUM DIGOXIN CONCENTRATION,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 01:59:51,,1323281361,7/15/2014 01:59:41,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlations,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 03:22:41,,1323316424,7/15/2014 03:21:59,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION],[MANIFESTATION],SUICIDAL DIGOXIN POISONING correlations SERUM DIGOXIN CONCENTRATION,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 03:24:16,,1323316941,7/15/2014 03:24:04,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlations,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 03:39:50,,1323322532,7/15/2014 03:38:38,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 04:33:11,,1323348361,7/15/2014 04:32:29,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],the correlations between,n/a,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 05:10:53,,1323360428,7/15/2014 05:10:15,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],correlations between,N/A,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 06:18:23,,1323381290,7/15/2014 06:17:32,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the correlations were studied.,SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007802,7/15/2014 06:36:20,,1323386515,7/15/2014 06:35:41,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlations,n/a,73,21,99,47,1,RO-has_causative_agent,903566-FS1,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
503007803,7/14/2014 20:43:28,,1323087418,7/14/2014 20:43:13,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],CONDITIONS ALLERGIC,N/A,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 21:06:11,,1323099378,7/14/2014 21:05:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],include,N/A,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 21:25:41,,1323108289,7/14/2014 21:25:26,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,n/a,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 21:48:33,,1323123096,7/14/2014 21:48:16,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC CONDITIONS ALLERGIC CONJUNCTIVITIS,n/a,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 21:49:10,,1323123466,7/14/2014 21:48:55,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],include,N/a,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 22:34:10,,1323147739,7/14/2014 22:33:41,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[IS_A],[IS_A],include,na,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 23:31:50,,1323173503,7/14/2014 23:31:19,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[SYMPTOM],[SYMPTOM],"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS asthma.",N/A,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/14/2014 23:45:35,,1323182496,7/14/2014 23:45:18,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[IS_A],[IS_A],ATOPIC CONDITIONS include ALLERGIC CONJUNCTIVITIS,na,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 00:36:37,,1323222076,7/15/2014 00:36:18,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],ATOPIC CONDITIONS include ALLERGIC CONJUNCTIVITIS,N/A,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 01:05:11,,1323244715,7/15/2014 01:04:51,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[MANIFESTATION],[MANIFESTATION],ATOPIC CONDITIONS,dsad,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 01:21:26,,1323255913,7/15/2014 01:20:51,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,NONE,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 01:48:33,,1323273738,7/15/2014 01:48:13,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],include,N/A,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 02:26:54,,1323294279,7/15/2014 02:26:25,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],ATOPIC CONDITIONS ALLERGIC CONJUNCTIVITIS,n/a,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 03:31:00,,1323318770,7/15/2014 03:29:07,elite,1.0,27788262,USA,"","",172.129.7.231,[OTHER],[OTHER],include,N/A,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007803,7/15/2014 05:07:00,,1323359001,7/15/2014 05:06:36,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,na,60,0,82,17,-1,RO-cause_of,900211-FS1,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
503007804,7/14/2014 21:07:09,,1323099884,7/14/2014 21:06:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examined,N/A,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/14/2014 21:25:12,,1323107988,7/14/2014 21:24:54,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],spontaneous behaviours in,n/a,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/14/2014 21:44:51,,1323120545,7/14/2014 21:44:01,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was examined for different spontaneous behaviours in,[DIAGNOSE_BY_TEST_OR_DRUG],109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/14/2014 21:50:49,,1323124294,7/14/2014 21:50:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],in,N/a,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/14/2014 22:25:39,,1323143979,7/14/2014 22:24:43,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],occurrence of,na,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/14/2014 22:44:35,,1323151696,7/14/2014 22:44:01,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examined for,N/A,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/14/2014 23:21:53,,1323169038,7/14/2014 23:21:02,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],was examined for different spontaneous behaviours,This is examining and it isnt in the relation option,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 00:34:12,,1323219961,7/15/2014 00:33:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"experiment,",n/a,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 01:07:17,,1323246319,7/15/2014 01:06:59,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[MANIFESTATION],[MANIFESTATION],occurrence,dsa,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 01:08:15,,1323246981,7/15/2014 01:07:46,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],occurrence,none,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 01:56:24,,1323278950,7/15/2014 01:56:07,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examined,N/A,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 02:04:48,,1323284372,7/15/2014 02:03:40,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ACUTE TOLERANCE DRUG NAIVE ANIMALS.,n/a,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 03:25:44,,1323317339,7/15/2014 03:25:29,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],occurrence,N/A,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 03:41:22,,1323323268,7/15/2014 03:39:52,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007804,7/15/2014 05:12:21,,1323360805,7/15/2014 05:11:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],examined for different spontaneous behaviours,n/a,109,40,126,55,-1,RO-has_causative_agent,903964-FS1,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
503007805,7/14/2014 20:39:48,,1323085677,7/14/2014 20:39:32,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],characteristics of,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 20:54:17,,1323093009,7/14/2014 20:53:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],regarding,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 21:16:16,,1323104057,7/14/2014 21:15:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],"Disagreement still exists regarding the influence of rosette formation,",N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 21:24:33,,1323107694,7/14/2014 21:24:15,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[IS_A],[IS_A],on the echographic characteristics,n/a,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 21:44:48,,1323120497,7/14/2014 21:43:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CALCIFICATION RETINOBLASTOMA,n/a,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 21:53:44,,1323125560,7/14/2014 21:53:00,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],CALCIFICATION echographic characteristics RETINOBLASTOMA,manifestation,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 22:11:42,,1323134949,7/14/2014 22:08:44,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],"influence necrotic changes,",na,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 22:53:39,,1323155575,7/14/2014 22:52:35,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION] [SIDE_EFFECT],"[MANIFESTATION]
[SIDE_EFFECT]",regarding the influence of CALCIFICATION on the echographic characteristics of RETINOBLASTOMA,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/14/2014 23:36:10,,1323176043,7/14/2014 23:35:27,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CALCIFICATION on the echographic characteristics of RETINOBLASTOMA,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/15/2014 00:39:43,,1323224698,7/15/2014 00:39:06,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],CALCIFICATION on the characteristics of RETINOBLASTOMA,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/15/2014 01:53:43,,1323277254,7/15/2014 01:53:25,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],characteristics,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/15/2014 02:50:59,,1323304354,7/15/2014 02:49:59,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],influence,not applicable,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/15/2014 03:11:45,,1323312838,7/15/2014 03:11:05,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],CALCIFICATION on RETINOBLASTOMA,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/15/2014 03:23:08,,1323316635,7/15/2014 03:22:53,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],characteristics,N/A,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007805,7/15/2014 03:34:40,,1323320147,7/15/2014 03:33:45,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,CALCIFICATION on the echographic characteristics of RETINOBLASTOMA,123,175,135,189,1,RO-disease_may_have_finding,902875-FS1,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
503007806,7/14/2014 21:14:58,,1323103443,7/14/2014 21:14:37,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],occurs in certain pathophysiological states such as,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 21:17:42,,1323104625,7/14/2014 21:17:07,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],occurs in certain pathophysiological states,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 21:20:56,,1323105979,7/14/2014 21:20:42,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],occurs in,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 21:23:19,,1323107098,7/14/2014 21:23:04,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 21:25:30,,1323108178,7/14/2014 21:25:13,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],occurs,n/a,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 21:47:22,,1323122471,7/14/2014 21:46:23,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[CAUSES],[CAUSES],occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 22:15:09,,1323137179,7/14/2014 22:14:25,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],occurs in,na,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 22:36:12,,1323148561,7/14/2014 22:35:48,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],occurs in,na,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/14/2014 22:52:34,,1323155071,7/14/2014 22:51:50,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],occurs in certain pathophysiological,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/15/2014 01:10:22,,1323248476,7/15/2014 01:10:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],occurs in,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/15/2014 01:53:01,,1323276773,7/15/2014 01:52:24,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],DEFICIENCY OF SULFUR PROTEIN CALORIE MALNUTRITION,n/a,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/15/2014 01:57:10,,1323279419,7/15/2014 01:56:51,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],occurs,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/15/2014 03:24:51,,1323317106,7/15/2014 03:24:34,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],such as,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/15/2014 03:32:58,,1323319485,7/15/2014 03:31:52,elite,1.0,27788262,USA,"","",172.129.7.231,[CAUSES],[CAUSES],occurs,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007806,7/15/2014 04:02:31,,1323333358,7/15/2014 04:02:00,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],occurs in certain,N/A,85,0,112,26,-1,RO-cause_of,900213-FS1,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
503007807,7/14/2014 21:23:18,,1323107087,7/14/2014 21:22:36,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],patients with,n/a,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 21:50:19,,1323124055,7/14/2014 21:49:49,neodev,1,21405167,USA,MD,Glen Burnie,69.137.237.73,[SYMPTOM],[SYMPTOM],METASTATIC LESIONS were resected during 107 operations in patients with PULMONARY METASTASES,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 21:56:51,,1323126609,7/14/2014 21:56:25,instagc,1,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],were resected during,N/a,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 22:04:32,,1323130483,7/14/2014 22:03:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],METASTATIC LESIONS were 100 patients PULMONARY METASTASES,manifestation,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 22:25:29,,1323143837,7/14/2014 22:24:27,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[SYMPTOM],[SYMPTOM],METASTATIC LESIONS were resected,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 22:31:15,,1323146521,7/14/2014 22:30:22,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],were resected,na,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 22:46:59,,1323152603,7/14/2014 22:46:30,instagc,1,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 22:50:47,,1323154228,7/14/2014 22:50:28,bitcoinget,1,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],in patients with,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/14/2014 22:55:42,,1323156482,7/14/2014 22:55:05,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],were resected with,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/15/2014 00:38:31,,1323223644,7/15/2014 00:35:37,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],in 100 patients with,n/a,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/15/2014 01:12:13,,1323249726,7/15/2014 01:11:48,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[LOCATION],[LOCATION],September,dsaw,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/15/2014 01:21:56,,1323256297,7/15/2014 01:21:27,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[SYMPTOM],[SYMPTOM],resected,NONE,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/15/2014 01:41:37,,1323269233,7/15/2014 01:40:50,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",were resected during operations,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/15/2014 01:57:47,,1323279843,7/15/2014 01:57:10,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[SIDE_EFFECT],[SIDE_EFFECT],with,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007807,7/15/2014 05:21:34,,1323364100,7/15/2014 05:20:56,vivatic,1,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],were resected in patients with,N/A,41,117,58,137,-1,RO-disease_has_finding,901700-FS1,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
503007808,7/14/2014 21:12:58,,1323102493,7/14/2014 21:12:39,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],causative agent,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 21:23:55,,1323107396,7/14/2014 21:23:42,neodev,1,15848372,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],the causative agent,n/a,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 21:24:19,,1323107579,7/14/2014 21:23:44,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],causative agent,n/a,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 21:29:38,,1323110541,7/14/2014 21:29:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],causative,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 21:53:07,,1323125306,7/14/2014 21:52:39,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],is the causative agent of,[CAUSES],0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 22:17:29,,1323138654,7/14/2014 22:16:06,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],causative agent,na,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 22:44:45,,1323151738,7/14/2014 22:44:36,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],causative agent,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/14/2014 23:33:01,,1323174136,7/14/2014 23:32:46,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[CAUSES],[CAUSES],BACILLUS ANTHRACIS is the causative agent of ANTHRAX,na,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 01:30:49,,1323262163,7/15/2014 01:30:10,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],is the causative agent of,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 02:27:52,,1323294709,7/15/2014 02:26:57,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],BACILLUS ANTHRACIS ANTHRAX,n/a,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 04:01:12,,1323332820,7/15/2014 04:00:42,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],causative agent,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 05:04:13,,1323358107,7/15/2014 05:03:49,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],causative agent,na,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 05:19:03,,1323363170,7/15/2014 05:18:40,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],causative agent,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 05:28:01,,1323366158,7/15/2014 05:27:44,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],causative agent,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007808,7/15/2014 05:40:30,,1323369992,7/15/2014 05:40:12,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],causative agent,N/A,0,45,17,52,1,RO-has_causative_agent,903605-FS1,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
503007809,7/14/2014 20:37:48,,1323084632,7/14/2014 20:37:41,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],include,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 20:43:48,,1323087613,7/14/2014 20:43:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],used in the second line treatment of,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 20:52:55,,1323092319,7/14/2014 20:52:24,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],treatment of HYPERCALCEMIA OF MALIGNANCY CALCITONIN,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 21:09:17,,1323100798,7/14/2014 21:08:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],second line treatment of,n/a,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 21:14:55,,1323103428,7/14/2014 21:14:37,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 21:43:43,,1323119560,7/14/2014 21:43:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Other agents treatment HYPERCALCEMIA OF MALIGNANCY CALCITONIN,treats,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 21:48:58,,1323123349,7/14/2014 21:48:45,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERCALCEMIA OF MALIGNANCY CALCITONIN,n/a,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 21:50:17,,1323124052,7/14/2014 21:48:00,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],second line treatment,na,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 21:56:51,,1323126607,7/14/2014 21:56:33,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],treatment,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 22:04:50,,1323130680,7/14/2014 22:04:06,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],include,n/a,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/14/2014 23:36:04,,1323176004,7/14/2014 23:35:47,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[TREATS],[TREATS],HYPERCALCEMIA OF MALIGNANCY include CALCITONIN,na,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/15/2014 02:51:50,,1323304760,7/15/2014 02:51:25,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment,not applicable,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/15/2014 03:17:41,,1323314842,7/15/2014 03:17:13,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],treatment of HYPERCALCEMIA OF MALIGNANCY include CALCITONIN,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/15/2014 05:09:34,,1323359889,7/15/2014 05:09:09,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],include,na,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007809,7/15/2014 05:32:35,,1323367641,7/15/2014 05:32:01,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treatment of,N/A,50,98,76,108,1,RO-may_treat,907491-FS1,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
503007810,7/14/2014 21:11:04,,1323101699,7/14/2014 21:10:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],agents,n/a,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/14/2014 21:18:07,,1323104836,7/14/2014 21:17:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Not indicated for the management of (either alone or in combination with weight loss agents such as,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/14/2014 22:49:41,,1323153767,7/14/2014 22:49:05,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[TREATS],[TREATS],weight loss agents such as,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/14/2014 23:34:31,,1323175019,7/14/2014 23:33:39,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[TREATS],[TREATS],management of EXOGENOUS OBESITY weight loss agents such as PHENTERMINE,na,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 01:19:35,,1323254696,7/15/2014 01:19:08,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],agents,NONE,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 03:11:03,,1323312557,7/15/2014 03:10:04,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],EXOGENOUS OBESITY weight loss agents PHENTERMINE,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 03:18:33,,1323315095,7/15/2014 03:18:17,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],weight loss agents,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 03:58:24,,1323331494,7/15/2014 03:57:55,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],weight loss agents,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 05:07:58,,1323359343,7/15/2014 05:07:33,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],combination with weight loss agents such as,n/a,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 05:15:30,,1323361934,7/15/2014 05:14:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CONTRAINDICATES],[CONTRAINDICATES],Not indicated,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 05:16:53,,1323362461,7/15/2014 05:16:29,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],indicated,na,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 05:38:55,,1323369461,7/15/2014 05:38:08,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],weight loss reported,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 06:05:58,,1323377903,7/15/2014 06:04:38,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CONTRAINDICATES],[CONTRAINDICATES],alone or in combination,either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 06:26:10,,1323383562,7/15/2014 06:25:32,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],weight loss agents,n/a,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007810,7/15/2014 07:23:37,,1323406292,7/15/2014 07:23:03,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],with weight loss agents such as,N/A,63,152,79,163,1,RO-may_treat,907893-FS1,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
503007811,7/14/2014 20:42:38,,1323086969,7/14/2014 20:42:30,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],characterize,n/a,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 20:57:45,,1323094846,7/14/2014 20:57:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],characterize,N/A,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 20:58:55,,1323095604,7/14/2014 20:58:26,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[PREVENTS],[PREVENTS],characterize,n/a,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 21:18:53,,1323105092,7/14/2014 21:18:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[SYMPTOM],[SYMPTOM],Different degrees of cerebral calcifications together,N/A,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 21:22:42,,1323106772,7/14/2014 21:22:24,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[IS_A],[IS_A],characterize the,n/a,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 21:26:05,,1323108575,7/14/2014 21:25:31,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterize,n/a,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 21:51:41,,1323124691,7/14/2014 21:50:53,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",characterize the,[IS_A] [PART_OF],92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 22:23:13,,1323142586,7/14/2014 22:22:24,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM] [MANIFESTATION] [ASSOCIATED_WITH],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",SEIZURE DISORDERS characterize STURGE WEBER SYNDROME,Symptom/Manifestation/Associated with,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 22:32:08,,1323146931,7/14/2014 22:31:42,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],characterize the,na,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/14/2014 23:42:39,,1323180302,7/14/2014 23:41:21,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],SEIZURE DISORDERS characterize STURGE WEBER SYNDROME,n/a,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/15/2014 00:55:16,,1323236995,7/15/2014 00:54:53,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],characterize,n/a,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/15/2014 01:10:01,,1323248218,7/15/2014 01:09:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],characterize,N/A,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/15/2014 01:11:06,,1323248944,7/15/2014 01:10:45,prodege,1.0,2145087,USA,WV,Wheeling,71.199.112.204,[SYMPTOM],[SYMPTOM],characterize the,N/A,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/15/2014 01:17:58,,1323253619,7/15/2014 01:17:16,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",characterize,N/A,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007811,7/15/2014 01:22:59,,1323257036,7/15/2014 01:22:34,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],characterize,NONE,92,127,108,148,1,RO-has_manifestation,906322-FS1,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
503007812,7/14/2014 20:42:03,,1323086748,7/14/2014 20:41:56,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],which,n/a,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/14/2014 20:43:52,,1323087654,7/14/2014 20:42:56,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[PREVENTS] [ASSOCIATED_WITH],"[PREVENTS]
[ASSOCIATED_WITH]",preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/14/2014 21:15:42,,1323103802,7/14/2014 21:15:23,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PREVENTS],[PREVENTS],prevent,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/14/2014 21:38:01,,1323115204,7/14/2014 21:36:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FUNCTIONAL LIVER BLOOD FLOW and LIVER ATROPHY,n/a,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/14/2014 21:46:22,,1323121679,7/14/2014 21:45:29,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/14/2014 21:51:10,,1323124503,7/14/2014 21:50:08,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[PREVENTS],[PREVENTS],and prevent,none,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/14/2014 22:26:29,,1323144364,7/14/2014 22:25:37,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY,Associated With,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 00:37:22,,1323222629,7/15/2014 00:36:38,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],FUNCTIONAL LIVER BLOOD FLOW and LIVER ATROPHY,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 01:05:57,,1323245297,7/15/2014 01:05:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],prevent,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 01:50:30,,1323275028,7/15/2014 01:50:09,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PREVENTS],[PREVENTS],prevent,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 02:35:08,,1323297545,7/15/2014 02:34:45,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[PREVENTS],[PREVENTS],FUNCTIONAL LIVER BLOOD FLOW LIVER ATROPHY,n/a,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 05:09:04,,1323359697,7/15/2014 05:08:48,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],and prevent,n/a,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 05:12:12,,1323360751,7/15/2014 05:11:37,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],preserve and prevent,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 05:19:34,,1323363392,7/15/2014 05:19:05,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[PREVENTS],[PREVENTS],prevent,na,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007812,7/15/2014 05:41:09,,1323370201,7/15/2014 05:40:31,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",These results which preserve,N/A,95,135,121,148,1,RO-has_finding_site,905234-FS1,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
503007813,7/14/2014 20:43:38,,1323087537,7/14/2014 20:43:31,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],epidermal,n/a,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 20:44:25,,1323087893,7/14/2014 20:44:12,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],VIRUS,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 20:56:23,,1323094059,7/14/2014 20:56:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],caused by,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 21:13:28,,1323102711,7/14/2014 21:13:12,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],caused by,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 21:21:41,,1323106306,7/14/2014 21:21:30,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],caused,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 21:22:22,,1323106638,7/14/2014 21:22:06,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],caused,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 21:47:59,,1323122807,7/14/2014 21:47:18,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],caused by,na,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 22:23:37,,1323142825,7/14/2014 22:22:28,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],caused by the,na,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 22:30:41,,1323146286,7/14/2014 22:30:02,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[CAUSES],[CAUSES],caused by,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 22:47:03,,1323152642,7/14/2014 22:46:42,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],caused by,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/14/2014 22:56:16,,1323156691,7/14/2014 22:55:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],caused by the,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/15/2014 01:16:52,,1323252907,7/15/2014 01:16:29,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],caused by,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/15/2014 01:43:46,,1323270646,7/15/2014 01:43:06,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",caused by,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/15/2014 01:50:42,,1323275200,7/15/2014 01:50:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],VERRUCA VULGARIS WART VIRUS,n/a,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007813,7/15/2014 01:55:32,,1323278324,7/15/2014 01:55:11,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],caused,N/A,89,16,98,32,1,RO-has_causative_agent,903573-FS1,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
503007814,7/14/2014 20:54:13,,1323092970,7/14/2014 20:53:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INFECTIOUS MONONUCLEOSIS followed by FEVER,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/14/2014 21:12:37,,1323102360,7/14/2014 21:12:03,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],followed by,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/14/2014 21:28:46,,1323110061,7/14/2014 21:28:31,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],followed by,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/14/2014 21:50:34,,1323124191,7/14/2014 21:49:51,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],INFECTIOUS MONONUCLEOSIS followed by FEVER,symptom,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/14/2014 22:18:30,,1323139371,7/14/2014 22:17:59,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed by,n/a,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/14/2014 22:27:47,,1323145136,7/14/2014 22:27:06,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SIDE_EFFECT],[SIDE_EFFECT],followed by,na,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 01:12:51,,1323250085,7/15/2014 01:12:21,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed,none,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 01:13:39,,1323250778,7/15/2014 01:13:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],followed by,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 01:54:15,,1323277564,7/15/2014 01:53:43,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SIDE_EFFECT],[SIDE_EFFECT],followed,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 02:06:16,,1323285053,7/15/2014 02:05:40,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],INFECTIOUS MONONUCLEOSIS FEVER,n/a,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 02:21:11,,1323292032,7/15/2014 02:20:28,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],INFECTIOUS MONONUCLEOSIS FEVER,n/a,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 03:18:11,,1323314989,7/15/2014 03:17:42,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],INFECTIOUS MONONUCLEOSIS followed by FEVER,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 03:25:59,,1323317408,7/15/2014 03:25:45,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],followed by,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 05:09:07,,1323359700,7/15/2014 05:08:40,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",followed by,na,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007814,7/15/2014 05:36:47,,1323368858,7/15/2014 05:36:28,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],followed by,N/A,99,62,103,86,1,RO-disease_has_finding,901550-FS1,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
503007815,7/14/2014 20:41:04,,1323086268,7/14/2014 20:39:50,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SKIN,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/14/2014 22:07:24,,1323132348,7/14/2014 22:06:29,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],"ECZEMA hands; 4 SKIN symptoms airborne areas, wrists, neck face.",Location,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/14/2014 22:36:14,,1323148567,7/14/2014 22:35:38,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]","All patients had ECZEMA on their hands; SKIN symptoms on airborne areas, i.e., wrists, neck and face.",N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/14/2014 22:41:48,,1323150683,7/14/2014 22:39:11,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients had ECZEMA had SKIN symptoms,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/14/2014 22:50:27,,1323154076,7/14/2014 22:50:05,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],symptoms,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/14/2014 23:05:08,,1323161162,7/14/2014 23:04:37,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],had SKIN,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 00:34:43,,1323220372,7/15/2014 00:34:10,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],ECZEMA on their hands; SKIN symptoms,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 01:56:07,,1323278752,7/15/2014 01:55:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],on,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 03:20:17,,1323315629,7/15/2014 03:19:59,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[LOCATION],[LOCATION],had,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 04:31:46,,1323347829,7/15/2014 04:30:38,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],"symptoms on airborne areas,",N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 05:05:35,,1323358568,7/15/2014 05:05:04,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],on their hands;,n/a,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 05:08:53,,1323359637,7/15/2014 05:08:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],"in addition,",N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 06:14:30,,1323380232,7/15/2014 06:13:54,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[LOCATION],[LOCATION],on their hands;,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms",59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 06:52:07,,1323391211,7/15/2014 06:51:28,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[LOCATION],[LOCATION],on,n/a,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007815,7/15/2014 07:23:02,,1323406130,7/15/2014 07:22:40,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],on their hands;,N/A,59,17,62,23,1,RO-disease_has_primary_anatomic_site,902001-FS1,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
503007816,7/14/2014 20:36:35,,1323083962,7/14/2014 20:36:15,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PREVENTS],[PREVENTS],drug,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 20:41:55,,1323086682,7/14/2014 20:41:47,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],becomes,n/a,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 20:43:28,,1323087434,7/14/2014 20:43:15,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CONTRAINDICATES],[CONTRAINDICATES],Discontinue,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 21:22:04,,1323106478,7/14/2014 21:21:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CONTRAINDICATES],[CONTRAINDICATES],Discontinue,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 21:23:44,,1323107300,7/14/2014 21:23:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CONTRAINDICATES],[CONTRAINDICATES],Discontinue,n/a,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 21:26:10,,1323108615,7/14/2014 21:25:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],inadvertently,n/a,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 21:51:06,,1323124448,7/14/2014 21:50:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],drug is administered,N/a,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 22:35:46,,1323148377,7/14/2014 22:35:24,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CONTRAINDICATES],[CONTRAINDICATES],Discontinue,na,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/14/2014 22:54:24,,1323155924,7/14/2014 22:53:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],Discontinue drug is administered inadvertently during,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/15/2014 00:39:45,,1323224705,7/15/2014 00:38:31,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],Discontinue,This drug should not be taken during pregnancy,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/15/2014 00:43:56,,1323227967,7/15/2014 00:43:00,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],Discontinue LEFLUNOMIDE if drug is administered during PREGNANCY,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/15/2014 01:05:41,,1323245139,7/15/2014 01:05:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[CONTRAINDICATES],[CONTRAINDICATES],Discontinue if administered during PREGNANCY,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/15/2014 01:11:07,,1323248956,7/15/2014 01:10:45,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[PREVENTS],[PREVENTS],LEFLUNOMIDE,dawdw,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/15/2014 01:58:44,,1323280596,7/15/2014 01:58:11,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Drug for pregnancy,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007816,7/15/2014 03:07:04,,1323311008,7/15/2014 03:05:55,clixsense,1.0,14466721,CAN,ON,Hamilton,216.209.129.175,[CONTRAINDICATES],[CONTRAINDICATES],Discontinue the drug,N/A,73,12,81,23,1,RO-contraindicated_drug,901397-FS1,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
503007817,7/14/2014 21:13:37,,1323102778,7/14/2014 21:13:18,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FORMALDEHYDE FORMALDEHYDE,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/14/2014 21:48:54,,1323123339,7/14/2014 21:48:03,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[PART_OF],[PART_OF],was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/14/2014 22:19:53,,1323140283,7/14/2014 22:18:35,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],partly reversible,na,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/14/2014 22:46:42,,1323152489,7/14/2014 22:45:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[IS_A],[IS_A],because once the,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/14/2014 23:00:17,,1323158808,7/14/2014 22:59:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],because once the FORMALDEHYDE CONCENTRATION was removed,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/14/2014 23:27:15,,1323171217,7/14/2014 23:26:02,gifthulk,1,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],FORMALDEHYDE TOXICITY was partly reversible once the FORMALDEHYDE CONCENTRATION was removed,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/14/2014 23:36:55,,1323176492,7/14/2014 23:36:11,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],TOXICITY partly reversible because once the FORMALDEHYDE CONCENTRATION,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 01:04:21,,1323244120,7/15/2014 01:04:02,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",partially,dsa,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 01:14:28,,1323251268,7/15/2014 01:12:54,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",once removed partially recovered.,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 03:21:42,,1323316095,7/15/2014 03:21:18,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],reversible,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 03:50:59,,1323327792,7/15/2014 03:50:43,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[PREVENTS],[PREVENTS],partly reversible,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 04:05:43,,1323334920,7/15/2014 04:05:11,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",FORMALDEHYDE TOXICITY FORMALDEHYDE CONCENTRATION,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 04:35:02,,1323349005,7/15/2014 04:34:05,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[CAUSES],[CAUSES],reversible once the removed,N/A,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 05:07:02,,1323359019,7/15/2014 05:06:13,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],"removed from the system,",n/a,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007817,7/15/2014 06:10:03,,1323379075,7/15/2014 06:09:24,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[TREATS],[TREATS],partly reversible,FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION,61,0,86,21,1,RO-has_causative_agent,903610-FS1,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
503007818,7/14/2014 20:40:36,,1323086060,7/14/2014 20:40:28,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],muscle,n/a,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 20:43:12,,1323087272,7/14/2014 20:42:57,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],implanted,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 20:50:44,,1323091192,7/14/2014 20:49:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION] [PREVENTS],"[PREVENTS]
[LOCATION]",implanted was compared,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 21:11:42,,1323101987,7/14/2014 21:11:06,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],to effect a recovery,n/a,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 21:13:11,,1323102586,7/14/2014 21:12:47,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],recovery from,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 22:05:35,,1323131177,7/14/2014 22:04:33,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION] [TREATS],"[TREATS]
[LOCATION]",PANCREATIC ISLETS implanted abdominal muscle effect recovery STREPTOZOTOCIN INDUCED DIABETES,Location/Treats,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 22:21:07,,1323141108,7/14/2014 22:20:44,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],implanted recovery,na,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 22:35:23,,1323148255,7/14/2014 22:34:58,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],to effect a recovery,na,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 22:56:43,,1323156831,7/14/2014 22:56:27,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],effect a recovery from,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/14/2014 23:31:18,,1323173241,7/14/2014 23:29:42,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,sorry but i am kind of confused as to what this sentence meant,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/15/2014 00:24:10,,1323211623,7/15/2014 00:23:12,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],PANCREATIC ISLETS effect a recovery from STREPTOZOTOCIN INDUCED DIABETES,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/15/2014 01:25:40,,1323258875,7/15/2014 01:24:57,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",recovery from,NONE,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/15/2014 03:25:28,,1323317291,7/15/2014 03:25:13,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],recovery,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/15/2014 03:56:46,,1323330657,7/15/2014 03:55:43,elite,1.0,27788262,USA,"","",172.129.7.231,[TREATS],[TREATS],to effect a recovery from,N/A,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007818,7/15/2014 05:04:20,,1323358128,7/15/2014 05:03:41,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],to effect a recovery from,n/a,15,91,31,122,1,RO-disease_has_primary_anatomic_site,902403-FS1,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
503007819,7/14/2014 20:43:46,,1323087607,7/14/2014 20:43:29,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],protective effect,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 20:57:38,,1323094776,7/14/2014 20:56:02,clixsense,1.0,15189335,GBR,H9,London,188.29.165.118,[TREATS],[TREATS],protective effect the,Na,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:00:29,,1323096444,7/14/2014 20:59:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],been substantiated by,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:10:35,,1323101458,7/14/2014 21:09:57,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CONTRAINDICATES],[CONTRAINDICATES],effect,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:23:02,,1323106914,7/14/2014 21:22:44,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],protective effect of,n/a,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:51:00,,1323124404,7/14/2014 21:50:38,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CARIES FETAL FLUORIDE,n/a,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:51:25,,1323124612,7/14/2014 21:51:07,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],protective effect of the,N/a,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:57:44,,1323127034,7/14/2014 21:56:09,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],n/a,no relation has been found,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:59:29,,1323127886,7/14/2014 21:58:39,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],CARIES protective effect the FETAL FLUORIDE substantiated pertinent research.,treats,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 21:59:59,,1323128109,7/14/2014 21:58:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[SIDE_EFFECT],[SIDE_EFFECT],protective effect,na,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/14/2014 23:23:10,,1323169674,7/14/2014 23:22:18,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],protective effect of the FETAL FLUORIDE been substantiated by pertinent research.,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/15/2014 01:07:41,,1323246555,7/15/2014 01:07:11,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],protective effect,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/15/2014 03:18:16,,1323315000,7/15/2014 03:18:00,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[PREVENTS],[PREVENTS],protective effect,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/15/2014 05:08:38,,1323359582,7/15/2014 05:08:13,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],effect,na,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007819,7/15/2014 05:21:57,,1323364231,7/15/2014 05:20:53,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION] [TREATS],"[TREATS]
[MANIFESTATION]",protective effect,N/A,3,35,8,49,1,RO-may_prevent,907148-FS1,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
503007820,7/14/2014 20:37:21,,1323084380,7/14/2014 20:37:07,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],prescribed,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 20:41:02,,1323086240,7/14/2014 20:40:54,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],domestic,n/a,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 20:47:50,,1323089597,7/14/2014 20:47:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],is prevalent,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 20:57:16,,1323094566,7/14/2014 20:56:50,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],prescribed,n/a,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:02:43,,1323097556,7/14/2014 21:00:07,clixsense,1.0,15189335,GBR,H9,London,188.29.164.159,[TREATS],[TREATS],prescribed for,Na,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:03:56,,1323098295,7/14/2014 21:02:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],prescribed for,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:25:30,,1323108194,7/14/2014 21:24:58,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],prescribed for,n/a,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:30:49,,1323111157,7/14/2014 21:30:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],prescribed,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:34:41,,1323113231,7/14/2014 21:34:11,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CONTRAINDICATES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",is prescribed for,[CONTRAINDICATES] [DIAGNOSE_BY_TEST_OR_DRUG],176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:46:37,,1323121962,7/14/2014 21:46:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],is prescribed for,N/a,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 21:49:22,,1323123605,7/14/2014 21:49:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FLUORIDE CARIES PROPHYLACTIC PURPOSE.,n/a,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 22:32:18,,1323147008,7/14/2014 22:31:31,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 23:27:05,,1323171169,7/14/2014 23:25:54,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],The results show that high F groundwater is prevalent and emphasize,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/14/2014 23:27:48,,1323171454,7/14/2014 23:27:16,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007820,7/15/2014 00:23:10,,1323210878,7/15/2014 00:22:26,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,N/A,176,135,202,157,1,RO-may_prevent,907269-FS1,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
503007821,7/14/2014 20:41:57,,1323086703,7/14/2014 20:40:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT] [CONTRAINDICATES],"[CONTRAINDICATES]
[SIDE_EFFECT]",substitute is suspected,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/14/2014 21:01:35,,1323096959,7/14/2014 21:01:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Do not substitute for,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/14/2014 21:18:38,,1323105045,7/14/2014 21:18:10,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Do not substitute for IV DEXTROSE,n/a,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/14/2014 21:26:10,,1323108617,7/14/2014 21:25:51,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CONTRAINDICATES],[CONTRAINDICATES],substitute,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/14/2014 22:36:28,,1323148655,7/14/2014 22:36:00,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CONTRAINDICATES],[CONTRAINDICATES],Do not substitute,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 00:33:29,,1323219425,7/15/2014 00:32:25,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],Do not substitute for,n/a,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 01:29:00,,1323260967,7/15/2014 01:28:04,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Do not substitute for in emergency situations,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 02:00:49,,1323282048,7/15/2014 01:59:20,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IV DEXTROSE HYPOGLYCEMIA,n/a,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 03:14:10,,1323313792,7/15/2014 03:13:24,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CONTRAINDICATES],[CONTRAINDICATES],IV DEXTROSE HYPOGLYCEMIA,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 05:10:01,,1323360082,7/15/2014 05:09:15,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[TREATS],[TREATS],Do not substitute,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 05:15:16,,1323361856,7/15/2014 05:14:48,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],emergency situations,na,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 05:24:18,,1323364958,7/15/2014 05:22:28,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suspected,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 05:34:20,,1323368240,7/15/2014 05:33:45,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],Do not substitute,N/A,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 05:49:05,,1323372668,7/15/2014 05:46:03,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],suspected,suspected,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007821,7/15/2014 06:23:01,,1323382608,7/15/2014 06:22:20,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CONTRAINDICATES],[CONTRAINDICATES],Do not substitute,n/a,67,25,78,33,1,RO-may_treat,907545-FS1,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
503007822,7/14/2014 20:37:40,,1323084544,7/14/2014 20:37:22,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],induction therapy,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/14/2014 20:41:46,,1323086599,7/14/2014 20:41:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],induction,n/a,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/14/2014 21:13:24,,1323102677,7/14/2014 21:13:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],as induction therapy for,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/14/2014 21:29:22,,1323110377,7/14/2014 21:29:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],therapy,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/14/2014 21:33:48,,1323112737,7/14/2014 21:33:21,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],therapy,n/a,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/14/2014 21:41:31,,1323117859,7/14/2014 21:40:58,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],as induction therapy for,[TREATS],109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 00:32:25,,1323218509,7/15/2014 00:32:03,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],as induction therapy for,n/a,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 01:56:50,,1323279197,7/15/2014 01:56:25,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],therapy,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 02:31:07,,1323295948,7/15/2014 02:30:12,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],VALGANCICLOVIR CYTOMEGALOVIRUS RETINITIS,n/a,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 03:13:32,,1323313578,7/15/2014 03:12:36,clixsense,1.0,14466721,CAN,ON,Hamilton,216.209.129.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],controlled trial of as induction therapy for,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 03:16:33,,1323314498,7/15/2014 03:16:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],VALGANCICLOVIR as therapy for CYTOMEGALOVIRUS RETINITIS,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 03:43:06,,1323324087,7/15/2014 03:41:23,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 05:08:04,,1323359385,7/15/2014 05:07:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],therapy for,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 05:36:04,,1323368685,7/15/2014 05:35:39,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],induction therapy for,N/A,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007822,7/15/2014 06:19:38,,1323381565,7/15/2014 06:19:06,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[TREATS],[TREATS],as induction therapy,A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS,109,69,133,83,1,RO-may_treat,907821-FS1,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
503007823,7/14/2014 20:38:25,,1323084974,7/14/2014 20:37:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],presented,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/14/2014 21:04:52,,1323098782,7/14/2014 21:02:44,clixsense,1.0,15189335,GBR,H9,London,188.29.164.19,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presented at birth with,Na,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/14/2014 21:27:16,,1323109173,7/14/2014 21:26:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who presented at birth with,n/a,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/14/2014 21:52:05,,1323124860,7/14/2014 21:51:16,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],NEUROFIBROMATOSIS TYPE 1 presented with CONGENITAL PSEUDARTHROSIS OF THE ULNA,Location,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/14/2014 22:08:49,,1323133225,7/14/2014 22:07:44,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who presented at birth with,n/a,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/14/2014 22:42:35,,1323150955,7/14/2014 22:41:42,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[PART_OF],[PART_OF],presented at birth with,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/14/2014 22:45:39,,1323152062,7/14/2014 22:44:46,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],presented with,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 01:20:25,,1323255314,7/15/2014 01:19:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],presented with,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 01:51:39,,1323275852,7/15/2014 01:50:47,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NEUROFIBROMATOSIS TYPE 1 CONGENITAL PSEUDARTHROSIS OF THE ULNA,n/a,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 03:17:43,,1323314858,7/15/2014 03:17:30,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],presented,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 04:04:30,,1323334305,7/15/2014 04:01:46,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],children with NEUROFIBROMATOSIS TYPE 1 presented birth with CONGENITAL PSEUDARTHROSIS OF ULNA,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 05:06:40,,1323358876,7/15/2014 05:05:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who presented with,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 05:25:20,,1323365298,7/15/2014 05:24:50,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],presented at birth,N/A,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 06:07:37,,1323378388,7/15/2014 06:06:40,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[PART_OF],[PART_OF],who presented at birth with,NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007823,7/15/2014 06:25:29,,1323383324,7/15/2014 06:23:53,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,Do not see any relation.,71,18,107,42,1,RO-has_manifestation,906339-FS1,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
503007824,7/14/2014 21:27:56,,1323109492,7/14/2014 21:27:42,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],WITH,n/a,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/14/2014 21:30:31,,1323110999,7/14/2014 21:30:16,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/14/2014 21:50:14,,1323124037,7/14/2014 21:50:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",STERILE CIRRHOTIC WITH HEPATOCELLULAR,n/a,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/14/2014 22:30:30,,1323146179,7/14/2014 22:28:50,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[NONE],[NONE],N/A,This is a list of unrelated diseases.,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/14/2014 22:37:24,,1323149021,7/14/2014 22:35:33,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"patients with ascitic fluid polymorphonuclear cell count patients with STERILE CIRRHOTIC AScites, WITH HEPATOCELLULAR CARCinoma, other diseases were studied.",N/A,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/14/2014 22:40:13,,1323150004,7/14/2014 22:38:03,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION],[LOCATION],liver metastasis,N/A,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/14/2014 23:39:00,,1323177806,7/14/2014 23:37:02,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,Two conditions which both result in similar levels of cell count,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 00:54:53,,1323236692,7/15/2014 00:54:33,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 01:16:28,,1323252629,7/15/2014 01:16:03,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WITH,N/A,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 01:46:01,,1323272081,7/15/2014 01:45:18,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"STERILE CIRRHOTIC AScites, WITH HEPATOCELLULAR CARCinoma,",n/a,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 02:00:08,,1323281540,7/15/2014 01:59:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,comparing,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 03:37:22,,1323321359,7/15/2014 03:36:37,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,"STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma,",186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 03:51:31,,1323328039,7/15/2014 03:51:01,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were studied.,N/A,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 05:12:54,,1323361001,7/15/2014 05:12:22,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],ascitic fluid polymorphonuclear cell count,n/a,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007824,7/15/2014 05:37:04,,1323368943,7/15/2014 05:36:21,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were studied.,N/A,186,278,205,302,-1,RO-disease_may_have_finding,902776-FS1,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
503007825,7/14/2014 20:43:57,,1323087683,7/14/2014 20:43:51,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],patients,n/a,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 20:56:40,,1323094232,7/14/2014 20:56:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 21:15:06,,1323103507,7/14/2014 21:14:39,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],found in patients,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 21:47:22,,1323122469,7/14/2014 21:47:00,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],revealed haemophagocytosis similar,N/a,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 21:58:01,,1323127152,7/14/2014 21:57:31,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],HAEMOPHAGOCYTIC HAEMOPHAGOCYTOSIS,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 22:22:50,,1323142326,7/14/2014 22:21:56,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 22:30:20,,1323146082,7/14/2014 22:29:42,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prominent post mortem feature,na,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 23:22:56,,1323169577,7/14/2014 23:21:03,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar to that found in,n/a,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/14/2014 23:29:50,,1323172437,7/14/2014 23:28:22,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/15/2014 01:05:28,,1323244944,7/15/2014 01:05:14,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES],[CAUSES],patients,dsas,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/15/2014 01:06:47,,1323245971,7/15/2014 01:05:58,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],very prominent feature,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/15/2014 03:58:51,,1323331758,7/15/2014 03:58:25,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Post mortem analyses,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/15/2014 05:10:14,,1323360147,7/15/2014 05:09:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],such,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/15/2014 05:27:42,,1323366004,7/15/2014 05:27:12,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007825,7/15/2014 06:10:07,,1323379085,7/15/2014 06:07:57,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[SYMPTOM],[SYMPTOM],found in,N/A,161,113,177,148,1,RO-disease_has_finding,901841-FS1,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503007826,7/14/2014 20:59:35,,1323095979,7/14/2014 20:58:40,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],infection of,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/14/2014 21:00:21,,1323096378,7/14/2014 20:59:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],is considered to be a possible risk factor for onward transmission,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/14/2014 21:24:56,,1323107855,7/14/2014 21:24:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],possible risk factor,n/a,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/14/2014 21:31:11,,1323111401,7/14/2014 21:30:50,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],risk factor,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/14/2014 22:30:10,,1323146034,7/14/2014 22:29:27,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[SYMPTOM],[SYMPTOM],Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB),N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 01:08:59,,1323247464,7/15/2014 01:08:43,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[TREATS],[TREATS],BOVINE TUBERCULOSIS,dsaw,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 01:10:44,,1323248755,7/15/2014 01:09:20,prodege,1.0,2145087,USA,WV,Wheeling,71.199.112.204,[SYMPTOM],[SYMPTOM],risk factor for,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 02:46:11,,1323302074,7/15/2014 02:45:17,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests.,not applicable,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 04:00:02,,1323332332,7/15/2014 03:59:24,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],possible risk factor,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 04:32:08,,1323347988,7/15/2014 04:31:27,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[CAUSES],[CAUSES],possible risk factor for onward transmission,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 05:11:55,,1323360703,7/15/2014 05:11:24,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS,n/a,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 05:29:09,,1323366600,7/15/2014 05:28:42,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],risk factor for onward transmission,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 06:03:57,,1323377327,7/15/2014 06:02:59,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],is considered to be a possible risk factor for onward transmission,MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 06:17:41,,1323381107,7/15/2014 06:15:58,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES] [OTHER],"[CAUSES]
[OTHER]",risk for onward transmission,N/A,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007826,7/15/2014 06:54:48,,1323392079,7/15/2014 06:53:57,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",possible risk factor,n/a,76,166,94,191,-1,RO-has_causative_agent,903869-FS1,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
503007827,7/14/2014 20:52:22,,1323092012,7/14/2014 20:51:57,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],METASTATIC LESIONS in patients with LIVER METASTASIS,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/14/2014 21:09:14,,1323100790,7/14/2014 21:07:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],in patients with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/14/2014 21:15:13,,1323103574,7/14/2014 21:14:57,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],in patients with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/14/2014 22:34:01,,1323147663,7/14/2014 22:33:42,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[IS_A],[IS_A],patients with,na,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/14/2014 23:01:21,,1323159429,7/14/2014 23:00:50,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],in patients with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/14/2014 23:36:28,,1323176207,7/14/2014 23:36:06,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[CAUSES],[CAUSES],primary lesions patients METASTATIC LESIONS with LIVER METASTASIS,na,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 01:09:38,,1323247929,7/15/2014 01:09:21,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[SYMPTOM] [IS_A],"[SYMPTOM]
[IS_A]",without metastasis,dsaw,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 01:11:39,,1323249356,7/15/2014 01:10:23,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],in patients with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 01:24:31,,1323258039,7/15/2014 01:23:47,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",in patients with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 01:49:03,,1323274091,7/15/2014 01:48:34,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 03:57:55,,1323331258,7/15/2014 03:57:32,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were studied.,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 03:59:15,,1323331927,7/15/2014 03:58:31,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 04:33:42,,1323348538,7/15/2014 04:31:47,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],with,N/A,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 05:13:33,,1323361254,7/15/2014 05:13:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],METASTATIC LESIONS in patients with LIVER METASTASIS,n/a,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007827,7/15/2014 05:18:11,,1323362841,7/15/2014 05:17:42,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],in patients,na,77,113,94,129,-1,RO-disease_has_finding,901605-FS1,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
503007828,7/14/2014 20:48:43,,1323090068,7/14/2014 20:47:04,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[NONE],[NONE],N/A,again. .there  is a question about the relationship so I so NO,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 21:21:24,,1323106163,7/14/2014 21:20:53,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],"comorbidity,",n/a,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 21:35:44,,1323113841,7/14/2014 21:35:02,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],"comorbidity,",[CAUSES],105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 21:46:02,,1323121478,7/14/2014 21:45:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Migraine patients,N/a,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 22:16:05,,1323137790,7/14/2014 22:15:09,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],direct interview,na,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 22:49:41,,1323153769,7/14/2014 22:49:21,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],healthcare utilization,N/A,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 23:03:06,,1323160369,7/14/2014 23:02:19,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],structured direct interview their side effects,N/A,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/14/2014 23:39:17,,1323177959,7/14/2014 23:38:35,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[SIDE_EFFECT],[SIDE_EFFECT],HEADACHE TREATMENTS and their side and healthcare utilization,n/a,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 00:41:53,,1323226416,7/15/2014 00:41:27,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],MIGRAINE DIAGNOSIS HEADACHE TREATMENTS and their side effects,N/A,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 01:09:57,,1323248177,7/15/2014 01:09:42,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",underwent,dsaw,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 03:26:21,,1323317522,7/15/2014 03:25:05,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,MIGRAINE DIAGNOSIS comorbidity and HEADACHE TREATMENTS,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 03:27:20,,1323317816,7/15/2014 03:26:28,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF],[PART_OF],about previous MIGRAINE DIAGNOSIS HEADACHE TREATMENTS,N/A,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 05:18:36,,1323363002,7/15/2014 05:18:11,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],"comorbidity,",na,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 05:24:11,,1323364921,7/15/2014 05:23:32,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],TREATMENTS,N/A,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007828,7/15/2014 05:36:20,,1323368735,7/15/2014 05:34:55,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",side effects,N/A,105,73,123,91,-1,RO-has_definitional_manifestation,904719-FS1,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
503007829,7/14/2014 20:41:09,,1323086325,7/14/2014 20:41:03,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],"characteristics,",n/a,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/14/2014 21:05:57,,1323099252,7/14/2014 21:05:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],multiple meningiomas with,N/A,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/14/2014 21:18:56,,1323105115,7/14/2014 21:18:37,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],such as,n/a,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/14/2014 22:32:35,,1323147113,7/14/2014 22:32:09,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and CENTRAL NEUROFIBROMATOSIS,na,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/14/2014 23:32:42,,1323173964,7/14/2014 23:31:51,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,N/A,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 01:12:34,,1323249949,7/15/2014 01:12:16,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CENTRAL NEUROFIBROMATOSIS,dsaw,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 01:49:57,,1323274749,7/15/2014 01:48:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INVASIVE MENINGIOMA CENTRAL NEUROFIBROMATOSIS,n/a,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 03:23:25,,1323316728,7/15/2014 03:23:08,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 05:33:20,,1323367896,7/15/2014 05:32:41,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],"aggressive characteristics,",N/A,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 06:17:30,,1323381034,7/15/2014 06:16:50,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[NONE],[NONE],N/A,N/A,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 06:34:01,,1323385815,7/15/2014 06:33:24,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM],[SYMPTOM],"malignant meningioma, hemangiopericytic meningioma, multiple meningiomas",n/a,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 07:28:04,,1323407872,7/15/2014 07:27:22,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,UNrelated symptoms for different conditions.,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 07:47:00,,1323414692,7/15/2014 07:45:42,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],with,n/a,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 07:57:51,,1323418569,7/15/2014 07:55:01,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[NONE],[NONE],N/A,The two terms represent characteristics of different menigiomas,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007829,7/15/2014 08:18:29,,1323426995,7/15/2014 08:18:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,79,181,97,206,-1,RO-has_manifestation,906180-FS1,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
503007830,7/14/2014 20:47:20,,1323089341,7/14/2014 20:46:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",associated with use of,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/14/2014 21:26:26,,1323108720,7/14/2014 21:26:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/14/2014 21:34:12,,1323112965,7/14/2014 21:33:49,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/14/2014 21:45:02,,1323120643,7/14/2014 21:44:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],associated with use of,N/a,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/14/2014 22:03:21,,1323129869,7/14/2014 22:02:41,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],associated with use of,n/a,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/14/2014 22:33:41,,1323147499,7/14/2014 22:33:17,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[SIDE_EFFECT],[SIDE_EFFECT],associated with use,na,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/14/2014 22:37:48,,1323149120,7/14/2014 22:36:48,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[CAUSES],[CAUSES],associated with use of,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 01:08:39,,1323247212,7/15/2014 01:08:23,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[SYMPTOM],[SYMPTOM],POLIOMYELITIS,dsadw,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 01:11:13,,1323249027,7/15/2014 01:10:29,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],associated with use of,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 01:18:02,,1323253665,7/15/2014 01:17:31,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 05:06:12,,1323358732,7/15/2014 05:05:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with use of,n/a,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 05:23:31,,1323364728,7/15/2014 05:22:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],associated with use of,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 06:06:39,,1323378070,7/15/2014 06:05:59,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with use of,cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 06:26:34,,1323383674,7/15/2014 06:26:12,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007830,7/15/2014 07:31:13,,1323409093,7/15/2014 07:30:40,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],associated with use of,N/A,170,217,192,240,1,RO-may_prevent,907152-FS1,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
503007831,7/14/2014 20:45:08,,1323088250,7/14/2014 20:44:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],provided,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 21:26:34,,1323108807,7/14/2014 21:26:11,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],increased,n/a,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 21:55:33,,1323126188,7/14/2014 21:54:37,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],treatment,N/a,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 21:56:33,,1323126486,7/14/2014 21:56:02,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[CAUSES],[CAUSES],NICOTINE ADDICTION NICOTINE,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 22:15:01,,1323137096,7/14/2014 22:12:29,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],increased the odds of counselors' providing,n/a,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 22:20:06,,1323140427,7/14/2014 22:19:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NICOTINE ADDICTION education treatment increased counselors' providing NICOTINE counseling.,associated with,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 22:41:37,,1323150595,7/14/2014 22:40:48,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 22:49:01,,1323153439,7/14/2014 22:48:18,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[MANIFESTATION],[MANIFESTATION],NICOTINE,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/14/2014 22:56:26,,1323156730,7/14/2014 22:55:06,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],the effects of,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/15/2014 01:18:42,,1323254089,7/15/2014 01:17:48,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,NONE,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/15/2014 02:20:26,,1323291730,7/15/2014 02:19:31,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],NICOTINE ADDICTION NICOTINE counseling.,n/a,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/15/2014 03:19:39,,1323315398,7/15/2014 03:19:14,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],providing,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/15/2014 03:28:57,,1323318208,7/15/2014 03:28:17,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],NICOTINE ADDICTION treatment NICOTINE,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/15/2014 04:01:59,,1323333166,7/15/2014 04:01:13,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],education or treatment,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007831,7/15/2014 04:50:00,,1323353324,7/15/2014 04:48:59,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[CAUSES],[CAUSES],treatment increased,N/A,96,96,103,114,-1,RO-has_causative_agent,903591-FS1,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
503007832,7/14/2014 20:36:50,,1323084075,7/14/2014 20:36:36,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 21:03:58,,1323098333,7/14/2014 21:03:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],injection of VASOPRESSIN favoured a diagnosis of complete DIABETES INSIPIDUS,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 21:25:21,,1323108088,7/14/2014 21:25:02,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],favoured,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 21:34:25,,1323113114,7/14/2014 21:34:04,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed by,n/a,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 21:49:34,,1323123730,7/14/2014 21:49:12,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],intravenous injection of,N/a,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 22:15:53,,1323137676,7/14/2014 22:15:02,zoombucks,1,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],favoured diagnosis of complete,n/a,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 22:23:12,,1323142576,7/14/2014 22:20:47,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],injection of VASOPRESSIN favoured diagnosis complete DIABETES INSIPIDUS,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 22:27:01,,1323144716,7/14/2014 22:26:32,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Results of restriction of liquids followed by intravenous injection of VASOPRESSIN favoured a diagnosis of complete DIABETES INSIPIDUS,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/14/2014 23:04:36,,1323160910,7/14/2014 23:03:55,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],favoured diagnosis complete,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/15/2014 01:22:33,,1323256728,7/15/2014 01:21:58,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,NONE,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/15/2014 03:57:53,,1323331254,7/15/2014 03:56:48,elite,1.0,27788262,USA,"","",172.129.7.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],(Miller test) favoured a diagnosis of complete,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/15/2014 05:37:42,,1323369139,7/15/2014 05:37:05,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Results,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/15/2014 06:21:05,,1323381982,7/15/2014 06:20:25,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],favoured a diagnosis of,by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/15/2014 06:31:49,,1323385090,7/15/2014 06:31:19,sendearnings,1,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],favoured diagnosis complete,n/a,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007832,7/15/2014 07:31:35,,1323409253,7/15/2014 07:31:13,prodege,1,22031444,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],favoured a diagnosis of,N/A,130,71,147,82,1,RO-may_diagnose,906588-FS1,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
503007833,7/14/2014 20:40:16,,1323085864,7/14/2014 20:40:08,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],features,n/a,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/14/2014 20:55:17,,1323093510,7/14/2014 20:54:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],studied,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/14/2014 21:45:42,,1323121232,7/14/2014 21:45:20,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],submucosal layer,na,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/14/2014 22:35:10,,1323148165,7/14/2014 22:34:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[LOCATION],[LOCATION],CANCER in the layer of the STOMACH,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/14/2014 23:33:25,,1323174333,7/14/2014 23:32:43,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],four EARLY GASTRIC CANCER layer of the STOMACH,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 01:09:15,,1323247624,7/15/2014 01:08:46,instagc,1,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in the submucosal layer of the STOMACH,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 03:53:35,,1323328988,7/15/2014 03:53:14,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied the clinicopathological features,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 05:09:14,,1323359753,7/15/2014 05:08:31,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],in submucosal layer of,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 05:09:57,,1323360066,7/15/2014 05:09:29,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],patients with DSCs in the submucosal layer the STOMACH,n/a,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 05:29:31,,1323366705,7/15/2014 05:29:10,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],in the,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 05:38:07,,1323369237,7/15/2014 05:37:43,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],We studied,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 06:27:09,,1323383808,7/15/2014 06:26:34,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[PART_OF],[PART_OF],the submucosal layer,n/a,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 07:26:30,,1323407304,7/15/2014 07:26:13,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],in the submucosal layer of the,N/A,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 07:26:45,,1323407393,7/15/2014 07:26:28,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],submucosal layer,Na,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007833,7/15/2014 07:51:21,,1323416043,7/15/2014 07:50:51,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,[LOCATION],[LOCATION],in the,n/a,123,52,129,72,1,RO-has_finding_site,905016-FS1,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
503007834,7/14/2014 20:40:45,,1323086124,7/14/2014 20:40:15,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],had,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 20:43:55,,1323087664,7/14/2014 20:43:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],PAIN,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 20:46:30,,1323088989,7/14/2014 20:45:54,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],lymphoma patients without IPSID had ABDOMINAL PAIN,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 21:27:01,,1323109017,7/14/2014 21:26:45,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 21:48:28,,1323123057,7/14/2014 21:47:51,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[PREVENTS],[PREVENTS],65% had,[PREVENTS],50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 21:57:30,,1323126916,7/14/2014 21:56:52,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],without IPSID had ABDOMINAL PAIN,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 22:12:29,,1323135395,7/14/2014 22:11:03,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[SIDE_EFFECT],[SIDE_EFFECT],had,n/a,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 22:27:30,,1323144975,7/14/2014 22:26:30,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]
[MANIFESTATION]",patients without IPSID ABDOMINAL PAIN,Manifestation/Symptom/Location,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 22:39:08,,1323149569,7/14/2014 22:37:25,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[CONTRAINDICATES],[CONTRAINDICATES],lymphoma patients without IPSID had ABDOMINAL PAIN,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/14/2014 22:40:22,,1323150057,7/14/2014 22:40:03,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],had,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/15/2014 01:17:30,,1323253373,7/15/2014 01:16:52,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],without IPSID had ABDOMINAL PAIN,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/15/2014 02:02:38,,1323283240,7/15/2014 02:02:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],IPSID ABDOMINAL PAIN,n/a,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/15/2014 03:19:58,,1323315518,7/15/2014 03:19:41,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],had,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/15/2014 03:31:50,,1323319061,7/15/2014 03:31:02,elite,1.0,27788262,USA,"","",172.129.7.231,[SYMPTOM],[SYMPTOM],had,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007834,7/15/2014 04:04:16,,1323334205,7/15/2014 04:03:41,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],ABDOMINAL PAIN,N/A,50,36,63,41,1,RO-disease_may_have_finding,902542-FS1,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
503007835,7/14/2014 21:03:14,,1323097868,7/14/2014 21:02:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],should be added to the list of immunopathies with a familial predisposition.,N/A,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:14:38,,1323103269,7/14/2014 21:14:15,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:14:48,,1323103346,7/14/2014 21:13:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,n/a,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:20:08,,1323105656,7/14/2014 21:19:37,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and MACROGLOBULINEMIA,N/A,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:22:22,,1323106633,7/14/2014 21:21:57,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:27:19,,1323109172,7/14/2014 21:26:51,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"undetermined significance,",n/a,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:47:03,,1323122274,7/14/2014 21:46:52,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MONOCLONAL GAMMOPATHY MACROGLOBULINEMIA,n/a,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:52:37,,1323125059,7/14/2014 21:51:43,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"of undetermined significance, multiple myeloma,",[DIAGNOSE_BY_TEST_OR_DRUG],87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 21:56:08,,1323126360,7/14/2014 21:54:05,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],n/a,It is so confusing I could not understand.,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/14/2014 22:59:41,,1323158437,7/14/2014 22:59:08,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],such as and,N/A,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/15/2014 00:42:36,,1323226979,7/15/2014 00:41:54,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",MONOCLONAL GAMMOPATHY and MACROGLOBULINEMIA should be immunopathies,N/A,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/15/2014 01:07:39,,1323246530,7/15/2014 01:07:21,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[MANIFESTATION],[MANIFESTATION],other MACROGLOBULINEMIA,dwads,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/15/2014 01:09:42,,1323247988,7/15/2014 01:08:57,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],familial occurrence,none,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/15/2014 01:19:48,,1323254858,7/15/2014 01:19:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],monoclonal gammopathies such as,N/A,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007835,7/15/2014 01:52:18,,1323276315,7/15/2014 01:51:45,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MONOCLONAL GAMMOPATHY MACROGLOBULINEMIA,n/a,87,161,107,178,-1,RO-disease_has_finding,901695-FS1,"Because of the occasional familial occurrence of other monoclonal gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance, multiple myeloma, and MACROGLOBULINEMIA of Waldenstr鐃緒申鐃緒申羝�申��申鐃緒申鐃緒申����渇���申amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
503007836,7/14/2014 20:38:22,,1323084926,7/14/2014 20:37:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in the tissue of,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 21:20:41,,1323105905,7/14/2014 21:20:20,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],in the tissue,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 21:25:50,,1323108368,7/14/2014 21:25:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],elevated,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 21:35:08,,1323113507,7/14/2014 21:34:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 21:54:36,,1323125879,7/14/2014 21:53:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],in the tissue of,N/a,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 22:22:43,,1323142200,7/14/2014 22:21:08,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[IS_A],[IS_A],islet cell tumors;,na,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 22:29:50,,1323145940,7/14/2014 22:28:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[LOCATION],[LOCATION],in the tissue of,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 22:51:03,,1323154354,7/14/2014 22:50:48,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],the tissue of,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/14/2014 23:42:13,,1323180011,7/14/2014 23:41:44,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[LOCATION],[LOCATION],normal ISLET CELLS concentration was elevated in tissue of ISLET CELL TUMORS,na,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/15/2014 01:06:31,,1323245756,7/15/2014 01:06:15,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],localized,dsasd,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/15/2014 03:17:12,,1323314682,7/15/2014 03:16:34,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF],[PART_OF],ISLET CELLS ISLET CELL TUMORS,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/15/2014 03:23:41,,1323316770,7/15/2014 03:23:26,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[LOCATION],[LOCATION],tissue,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/15/2014 05:25:15,,1323365264,7/15/2014 05:24:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],ISLET CELL TUMORS,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/15/2014 05:31:54,,1323367445,7/15/2014 05:31:19,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[LOCATION],[LOCATION],localized,N/A,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007836,7/15/2014 06:11:11,,1323379358,7/15/2014 06:10:04,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[PART_OF],[PART_OF],ISLET CELLS and islet cell tumors;,its concentration was elevated only in the tissue of ISLET CELL TUMORS,62,150,72,167,1,RO-disease_has_primary_anatomic_site,902422-FS1,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
503007837,7/14/2014 20:51:32,,1323091605,7/14/2014 20:50:18,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 20:58:39,,1323095421,7/14/2014 20:57:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],might be,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 21:00:49,,1323096612,7/14/2014 21:00:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],might be of prognostic value in the administration of,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 21:18:50,,1323105084,7/14/2014 21:18:20,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],prognostic value,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 21:21:47,,1323106333,7/14/2014 21:21:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Our results suggest,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 21:53:56,,1323125643,7/14/2014 21:53:41,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],administration of,N/a,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 22:06:27,,1323131752,7/14/2014 22:05:36,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],REENTRANT ARRHYTHMIAS prognostic value administration ANTIARRHYTHMIC DRUGS,Diagnosed by Test or Drug,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 22:35:48,,1323148408,7/14/2014 22:35:16,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[TREATS],[TREATS],the administration of,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 22:46:29,,1323152438,7/14/2014 22:45:48,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 22:49:21,,1323153583,7/14/2014 22:48:58,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],of prognostic value,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 23:00:49,,1323159160,7/14/2014 23:00:18,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",might be prognostic value,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/14/2014 23:40:26,,1323178704,7/14/2014 23:39:46,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,n/a,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/15/2014 00:28:13,,1323215060,7/15/2014 00:26:53,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],dependence of REENTRANT ARRHYTHMIAS administration of ANTIARRHYTHMIC DRUGS,N/A,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/15/2014 01:13:12,,1323250416,7/15/2014 01:12:57,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",dependence,dsaw,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007837,7/15/2014 02:08:42,,1323286380,7/15/2014 02:08:03,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",REENTRANT ARRHYTHMIAS ANTIARRHYTHMIC DRUGS,n/a,54,130,74,150,1,RO-may_prevent,907439-FS1,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
503007838,7/14/2014 20:44:14,,1323087832,7/14/2014 20:44:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],MIDDLE,n/a,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 20:58:49,,1323095509,7/14/2014 20:58:28,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],at the junction of the,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 21:10:08,,1323101257,7/14/2014 21:09:17,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],at the junction of the,n/a,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 21:19:11,,1323105215,7/14/2014 21:18:51,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],at the junction,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 21:21:43,,1323106308,7/14/2014 21:21:25,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],junction of the,n/a,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 21:40:56,,1323117333,7/14/2014 21:40:20,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",showed a fungating growth,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 22:11:02,,1323134540,7/14/2014 22:10:15,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],showed a fungating growth at the junction of the,n/a,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 22:26:55,,1323144649,7/14/2014 22:25:33,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[LOCATION],[LOCATION],at the junction of,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 22:48:11,,1323153112,7/14/2014 22:47:47,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION],[LOCATION],ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 23:01:47,,1323159706,7/14/2014 23:01:22,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],at the junction of,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/14/2014 23:21:02,,1323168560,7/14/2014 23:20:14,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],at the junction of,n/a,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/15/2014 00:34:09,,1323219895,7/15/2014 00:33:29,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",ESOPHAGEAL TUMOR showed growth at MIDDLE AND LOWER ESOPHAGUS,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/15/2014 01:50:46,,1323275232,7/15/2014 01:50:30,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],at,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/15/2014 02:24:03,,1323293169,7/15/2014 02:23:21,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],ESOPHAGEAL TUMOR MIDDLE AND LOWER ESOPHAGUS,n/a,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007838,7/15/2014 03:16:03,,1323314363,7/15/2014 03:15:11,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],ESOPHAGEAL TUMOR at the junction of MIDDLE AND LOWER ESOPHAGUS,N/A,70,4,95,20,1,RO-has_finding_site,905417-FS1,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
503007839,7/14/2014 20:39:29,,1323085525,7/14/2014 20:39:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],was a,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 21:04:34,,1323098633,7/14/2014 21:04:15,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],secondary to a,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 21:13:04,,1323102545,7/14/2014 21:11:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[SYMPTOM],[SYMPTOM],was secondary to a,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 21:16:03,,1323103953,7/14/2014 21:15:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was secondary to,n/a,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 21:32:13,,1323111920,7/14/2014 21:31:50,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],secondary,n/a,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 21:50:49,,1323124303,7/14/2014 21:49:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was secondary to,[DIAGNOSE_BY_TEST_OR_DRUG],0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 21:51:33,,1323124654,7/14/2014 21:51:05,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[SYMPTOM],[SYMPTOM],was secondary to PHAEOCHROMOCYTOMA,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 22:06:11,,1323131616,7/14/2014 22:03:56,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[SYMPTOM],[SYMPTOM],secondary,na,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 23:06:14,,1323161557,7/14/2014 23:05:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],was secondary to,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 23:24:24,,1323170152,7/14/2014 23:23:12,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[SYMPTOM],[SYMPTOM],FEVER was secondary to PHAEOCHROMOCYTOMA,Fever is a symptom to phaeochromocytoma,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/14/2014 23:41:43,,1323179674,7/14/2014 23:40:28,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FEVER was secondary to PHAEOCHROMOCYTOMA,na,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/15/2014 00:56:01,,1323237532,7/15/2014 00:55:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],secondary to,n/a,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/15/2014 01:12:03,,1323249641,7/15/2014 01:11:40,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],was secondary to,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/15/2014 01:19:07,,1323254433,7/15/2014 01:18:43,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],secondary,NONE,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007839,7/15/2014 01:53:06,,1323276859,7/15/2014 01:52:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],secondary,N/A,0,25,4,42,1,RO-disease_may_have_finding,902821-FS1,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
503007840,7/14/2014 20:40:15,,1323085866,7/14/2014 20:39:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],manifests of,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/14/2014 20:44:29,,1323087948,7/14/2014 20:44:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[MANIFESTATION],[MANIFESTATION],CANCER (SCLC) manifests NEUROENDOCRINE DIFFERENTIATION,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/14/2014 21:00:05,,1323096218,7/14/2014 20:59:33,clixsense,1.0,15189335,GBR,H9,London,188.29.165.118,[ASSOCIATED_WITH],[ASSOCIATED_WITH],manifests,Na,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/14/2014 21:53:39,,1323125511,7/14/2014 21:53:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],manifests a number of,N/a,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/14/2014 23:06:44,,1323161775,7/14/2014 23:06:15,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],manifests a number of,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/14/2014 23:27:59,,1323171582,7/14/2014 23:27:06,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[IS_A],[IS_A],Small cell lung CANCER manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 01:10:41,,1323248692,7/15/2014 01:10:26,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[PREVENTS],[PREVENTS],manifests,dsaw,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 02:07:07,,1323285405,7/15/2014 02:06:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[MANIFESTATION],[MANIFESTATION],CANCER (SCLC) NEUROENDOCRINE DIFFERENTIATION,n/a,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 02:17:20,,1323290335,7/15/2014 02:15:35,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[MANIFESTATION],[MANIFESTATION],CANCER (SCLC) NEUROENDOCRINE DIFFERENTIATION,n/a,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 02:56:10,,1323306423,7/15/2014 02:55:17,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",manifests a,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 04:09:42,,1323336926,7/15/2014 04:07:50,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[MANIFESTATION],[MANIFESTATION],CANCER (SCLC) manifests NEUROENDOCRINE DIFFERENTIATION,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 05:05:04,,1323358403,7/15/2014 05:04:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],manifests a number of,n/a,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 05:07:31,,1323359225,7/15/2014 05:07:06,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],manifests,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 06:56:40,,1323392677,7/15/2014 06:56:05,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],manifests a number of,n/a,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007840,7/15/2014 07:22:38,,1323406031,7/15/2014 07:22:14,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],manifests a number of,N/A,52,16,81,29,1,RO-disease_has_finding,901737-FS1,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
503007841,7/14/2014 20:44:10,,1323087791,7/14/2014 20:43:55,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 20:55:02,,1323093408,7/14/2014 20:54:47,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[PART_OF],[PART_OF],HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 20:56:00,,1323093872,7/14/2014 20:55:28,clixsense,1.0,15189335,GBR,H9,London,188.29.165.118,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,Na,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 20:57:06,,1323094466,7/14/2014 20:56:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 20:57:39,,1323094768,7/14/2014 20:57:17,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",representative associated,n/a,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 21:17:23,,1323104530,7/14/2014 21:16:44,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],in,n/a,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 21:18:22,,1323104918,7/14/2014 21:17:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],representative,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 21:45:17,,1323120863,7/14/2014 21:45:02,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",in,N/a,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 21:53:21,,1323125377,7/14/2014 21:50:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[SYMPTOM],[SYMPTOM],in,na,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 21:55:47,,1323126256,7/14/2014 21:55:29,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[SYMPTOM],[SYMPTOM],HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 22:17:59,,1323138986,7/14/2014 22:17:33,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],in,n/a,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 22:33:04,,1323147275,7/14/2014 22:32:17,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[MANIFESTATION],[MANIFESTATION],HYPERVISCOSITY ideal representative,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 22:51:58,,1323154814,7/14/2014 22:51:04,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],representative of,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 22:58:31,,1323157847,7/14/2014 22:58:04,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007841,7/14/2014 23:20:13,,1323168146,7/14/2014 23:18:55,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],in,n/a,13,31,26,62,1,RO-disease_may_have_finding,902947-FS1,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
503007842,7/14/2014 20:42:18,,1323086843,7/14/2014 20:42:10,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SPINE,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/14/2014 20:52:01,,1323091840,7/14/2014 20:50:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],analysing,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/14/2014 20:53:42,,1323092742,7/14/2014 20:52:57,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],"growing adolescent SPINE (for instance in SCOLIOSIS research),",'For example' relation,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/14/2014 21:35:53,,1323113918,7/14/2014 21:35:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPINE SCOLIOSIS,n/a,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/14/2014 22:26:29,,1323144357,7/14/2014 22:25:54,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION],[LOCATION],biomechanics of the growing adolescent SPINE,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 00:38:30,,1323223655,7/15/2014 00:37:48,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],"adolescent SPINE in SCOLIOSIS research),",N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 01:11:36,,1323249329,7/15/2014 01:10:53,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],biomechanics,none,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 02:23:19,,1323292985,7/15/2014 02:22:46,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPINE SCOLIOSIS,n/a,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 03:55:00,,1323329739,7/15/2014 03:54:43,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],analysing,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 05:10:19,,1323360161,7/15/2014 05:09:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],"instance in SCOLIOSIS research),",n/a,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 05:17:57,,1323362816,7/15/2014 05:17:05,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],"analysing the SPINE (for instance in SCOLIOSIS research),",N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 05:38:13,,1323369262,7/15/2014 05:37:55,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],(for instance in,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 06:11:13,,1323379363,7/15/2014 06:10:02,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(for instance in,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 06:18:33,,1323381305,7/15/2014 06:17:43,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],"depth and width changes,",N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007842,7/15/2014 07:26:11,,1323407237,7/15/2014 07:25:46,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],(for instance in,N/A,65,88,69,97,1,RO-has_finding_site,905141-FS1,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
503007843,7/14/2014 20:42:40,,1323086996,7/14/2014 20:42:19,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment prevention,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 20:43:13,,1323087278,7/14/2014 20:42:55,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],DEFEROXAMINE,n/a,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 20:51:55,,1323091800,7/14/2014 20:51:33,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 20:58:57,,1323095618,7/14/2014 20:57:41,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[TREATS],[TREATS],successes of DEFEROXAMINE (DFO) in treatment and prevention of IRON OVERLOAD,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 21:17:11,,1323104438,7/14/2014 21:16:57,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],treatment,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 21:19:51,,1323105546,7/14/2014 21:19:27,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment and prevention of,n/a,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 21:27:10,,1323109101,7/14/2014 21:26:54,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 21:44:59,,1323120632,7/14/2014 21:44:39,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment and prevention,na,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 22:01:45,,1323129022,7/14/2014 22:01:11,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",the treatment and prevention of,n/a,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 22:45:21,,1323151969,7/14/2014 22:44:19,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed,",N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 23:22:14,,1323169244,7/14/2014 23:21:32,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],successes of DEFEROXAMINE in the treatment and prevention of IRON OVERLOAD,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/14/2014 23:39:46,,1323178251,7/14/2014 23:39:02,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment and prevention,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/15/2014 00:43:33,,1323227617,7/15/2014 00:43:19,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment and prevention,n/a,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/15/2014 01:12:41,,1323250035,7/15/2014 01:12:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment and prevention of,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/15/2014 01:13:19,,1323250510,7/15/2014 01:12:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment and prevention of,N/A,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007843,7/15/2014 01:17:16,,1323253211,7/15/2014 01:16:21,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment prevention,none,79,25,91,37,1,RO-may_prevent,907321-FS1,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
503007844,7/14/2014 20:42:56,,1323087141,7/14/2014 20:42:41,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],disappeared,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/14/2014 20:56:20,,1323094047,7/14/2014 20:56:02,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],APNOEA disappeared in infants after administration of CAFFEINE,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/14/2014 21:12:45,,1323102421,7/14/2014 21:12:16,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],administration,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/14/2014 23:05:48,,1323161442,7/14/2014 23:05:10,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],disappeared in all infants after administration of,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/14/2014 23:21:00,,1323168543,7/14/2014 23:19:47,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],APNOEA disappeared in all infants,There was not really a relation this falls under,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 01:51:34,,1323275802,7/15/2014 01:51:08,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],administration,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 04:05:10,,1323334668,7/15/2014 04:04:31,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[TREATS],[TREATS],prolonged APNOEA disappeared in infants after administration of CAFFEINE,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 05:04:39,,1323358258,7/15/2014 05:03:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",after administration of,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 05:14:16,,1323361500,7/15/2014 05:13:47,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[LOCATION],[LOCATION],infants administration,na,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 06:09:22,,1323378890,7/15/2014 06:07:38,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[OTHER],[OTHER],disappeared in all infants after administration,prolonged APNOEA disappeared in all infants after administration of CAFFEINE,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 06:34:24,,1323385956,7/15/2014 06:34:03,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[PREVENTS],[PREVENTS],administration,n/a,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 07:28:29,,1323408049,7/15/2014 07:28:05,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],disappeared after administration of,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 07:45:41,,1323414224,7/15/2014 07:44:24,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],administration,n/a,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 08:18:16,,1323426911,7/15/2014 08:18:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],administration,Na,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007844,7/15/2014 08:34:52,,1323433639,7/15/2014 08:33:07,prodege,1,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],disappeared after administration,N/A,22,80,27,88,1,RO-may_treat,908015-FS1,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
503007845,7/14/2014 21:34:51,,1323113336,7/14/2014 21:32:59,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CONTRAINDICATES],[CONTRAINDICATES],resistance to,na,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/14/2014 22:51:23,,1323154534,7/14/2014 22:50:52,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and its resistance to,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/14/2014 22:54:25,,1323155931,7/14/2014 22:54:06,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],resistance to,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 01:03:31,,1323243507,7/15/2014 01:03:15,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[PREVENTS] [CONTRAINDICATES],"[PREVENTS]
[CONTRAINDICATES]",abnormalities:,fesdf,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 03:36:34,,1323320933,7/15/2014 03:35:42,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 04:01:45,,1323333037,7/15/2014 04:01:11,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],In MDD two biochemical abnormalities: HYPERCORTISOLISM DEXAMETHASONE,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 04:47:46,,1323352709,7/15/2014 04:46:59,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[MANIFESTATION],[MANIFESTATION],two biochemical abnormalities: resistance to,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 05:04:42,,1323358285,7/15/2014 05:04:13,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[PREVENTS],[PREVENTS],resistance,na,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 05:18:39,,1323363033,7/15/2014 05:18:00,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],abnormalities:,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 05:46:01,,1323371763,7/15/2014 05:44:35,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[NONE],[NONE],N/A,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 06:22:19,,1323382441,7/15/2014 06:20:42,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[OTHER],[OTHER],resistance,n/a,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 07:32:16,,1323409492,7/15/2014 07:31:36,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],and its resistance to,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 07:48:44,,1323415272,7/15/2014 07:47:02,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],resistance,n/a,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 07:58:53,,1323419070,7/15/2014 07:57:52,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007845,7/15/2014 08:18:57,,1323427168,7/15/2014 08:18:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],suppression.,Na,64,103,79,116,1,RO-may_diagnose,906872-FS1,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
503007846,7/14/2014 20:58:11,,1323095097,7/14/2014 20:57:49,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],"reaction to TUBERCULIN on admission, TUBERCULOSIS",N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/14/2014 21:22:34,,1323106701,7/14/2014 21:22:06,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],developed,N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/14/2014 21:43:19,,1323119221,7/14/2014 21:42:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN TUBERCULOSIS,n/a,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/14/2014 23:32:45,,1323173986,7/14/2014 23:32:16,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"reaction to TUBERCULIN on admission, developed TUBERCULOSIS",na,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 01:47:11,,1323272857,7/15/2014 01:46:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN TUBERCULOSIS,n/a,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 05:19:04,,1323363173,7/15/2014 05:18:37,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",developed,na,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 05:20:53,,1323363894,7/15/2014 05:20:15,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],developed,N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 06:13:08,,1323379866,7/15/2014 06:11:35,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],developed,N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 06:15:45,,1323380561,7/15/2014 06:15:13,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],developed,"reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 07:27:21,,1323407588,7/15/2014 07:26:32,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],"on admission, 2% to 3% of these developed",N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 07:52:27,,1323416470,7/15/2014 07:51:22,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],developed,n/a,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 08:18:45,,1323427077,7/15/2014 08:18:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],"admission,",Na,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 08:31:20,,1323431565,7/15/2014 08:30:53,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],reaction to,N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 08:53:38,,1323439629,7/15/2014 08:52:40,prodege,1,21891314,AUS,07,Glen Iris,58.6.248.249,[CAUSES],[CAUSES],"TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007846,7/15/2014 09:08:07,,1323445522,7/15/2014 09:07:10,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reaction,N/A,137,84,148,94,1,RO-may_diagnose,906630-FS1,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
503007847,7/14/2014 20:41:30,,1323086499,7/14/2014 20:41:15,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test to screen,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 21:11:16,,1323101767,7/14/2014 21:09:15,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is the recommended test to screen for,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 21:36:56,,1323114488,7/14/2014 21:35:51,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [CONTRAINDICATES],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",is the recommended test to,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [CONTRAINDICATES],196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 21:38:16,,1323115373,7/14/2014 21:38:01,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INTRADERMAL TUBERCULOSIS,n/a,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 21:56:24,,1323126453,7/14/2014 21:55:35,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is the recommended test to screen for,N/a,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 22:18:37,,1323139451,7/14/2014 22:16:02,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRADERMAL recommended test screen for TUBERCULOSIS,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 22:31:40,,1323146687,7/14/2014 22:31:15,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommended test to screen for,na,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/14/2014 22:48:48,,1323153301,7/14/2014 22:48:12,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 00:30:12,,1323216645,7/15/2014 00:29:02,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PPD INTRADERMAL recommended test to screen for TUBERCULOSIS infection.,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 01:18:25,,1323253919,7/15/2014 01:18:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommended test to screen,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 01:26:37,,1323259484,7/15/2014 01:26:09,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,NONE,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 01:30:09,,1323261700,7/15/2014 01:29:43,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommended test to screen for,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 04:02:58,,1323333557,7/15/2014 04:02:32,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommended test to screen,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 05:03:40,,1323357959,7/15/2014 05:03:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommended test to screen for,n/a,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007847,7/15/2014 05:18:11,,1323362842,7/15/2014 05:16:34,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommended test,N/A,196,142,207,157,1,RO-may_diagnose,906599-FS1,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
503007848,7/14/2014 20:42:21,,1323086876,7/14/2014 20:42:14,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],"failure,",n/a,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 20:57:03,,1323094438,7/14/2014 20:56:42,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],PYELONEPHRITIS and other diseases of the KIDNEYS,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:03:33,,1323098027,7/14/2014 21:03:14,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],and other diseases of the,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:21:08,,1323106051,7/14/2014 21:20:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],of the KIDNEYS,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:23:02,,1323106925,7/14/2014 21:22:48,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:43:09,,1323119111,7/14/2014 21:42:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],other diseases of,[CAUSES],105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:47:39,,1323122640,7/14/2014 21:47:23,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],and other diseases of the KIDNEYS,N/a,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:55:28,,1323126159,7/14/2014 21:55:09,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],of the KIDNEYS,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/14/2014 21:58:18,,1323127260,7/14/2014 21:55:42,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],other diseases,na,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/15/2014 00:55:37,,1323237246,7/15/2014 00:55:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],diseases of the,n/a,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/15/2014 01:08:56,,1323247414,7/15/2014 01:08:16,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],involved.,none,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/15/2014 01:16:02,,1323252327,7/15/2014 01:15:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],diseases of the,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/15/2014 02:24:52,,1323293493,7/15/2014 02:24:08,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PYELONEPHRITIS KIDNEYS,n/a,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/15/2014 02:54:41,,1323305813,7/15/2014 02:53:42,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],and other diseases of the KIDNEYS,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007848,7/15/2014 03:12:19,,1323313057,7/15/2014 03:11:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],PYELONEPHRITIS diseases of KIDNEYS,N/A,105,64,111,78,1,RO-has_finding_site,905268-FS1,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
503007849,7/14/2014 20:53:04,,1323092396,7/14/2014 20:52:02,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],have revealed,N/A,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 21:05:21,,1323098981,7/14/2014 21:04:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],examinations of 250 patients with have revealed,N/A,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 21:06:45,,1323099624,7/14/2014 21:05:41,clixsense,1.0,15189335,GBR,H9,London,188.29.164.19,[SYMPTOM],[SYMPTOM],have revealed,Na,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 21:13:45,,1323102820,7/14/2014 21:12:56,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],secondary candidal INVOLVEMENT,n/a,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 21:28:44,,1323110023,7/14/2014 21:28:15,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],revealed,n/a,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 22:10:14,,1323134003,7/14/2014 22:08:49,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have revealed secondary candidal,n/a,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 22:43:41,,1323151370,7/14/2014 22:42:40,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[MANIFESTATION],[MANIFESTATION],have revealed secondary candidal,N/A,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 22:47:46,,1323152958,7/14/2014 22:47:01,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",Clinical and laboratory examinations of 250 patients with chronic DERMATOSES have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,N/A,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 23:25:22,,1323170518,7/14/2014 23:22:57,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have revealed,n/a,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/14/2014 23:39:45,,1323178246,7/14/2014 23:39:18,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],n/a,n/a,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/15/2014 01:05:01,,1323244602,7/15/2014 01:04:19,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],have revealed secondary,N/A,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/15/2014 01:08:00,,1323246845,7/15/2014 01:07:42,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",patients OF,dwadsd,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/15/2014 01:15:18,,1323251846,7/15/2014 01:14:45,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],examinations,none,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/15/2014 01:18:40,,1323254067,7/15/2014 01:18:00,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[MANIFESTATION],[MANIFESTATION],have revealed secondary,N/A,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007849,7/15/2014 01:59:15,,1323280946,7/15/2014 01:58:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) INVOLVEMENT OF THE SKIN AND MUCOSA,n/a,159,66,192,125,1,RO-disease_has_primary_anatomic_site,902277-FS1,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
503007850,7/14/2014 20:45:07,,1323088249,7/14/2014 20:44:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],specialist in HYPERTENSION to confirming PHEOCHROMOCYTOMA,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 20:49:29,,1323090450,7/14/2014 20:48:55,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to assist in confirming the diagnosis,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 21:00:00,,1323096183,7/14/2014 20:59:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 21:07:59,,1323100258,7/14/2014 21:07:19,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],specialist,n/a,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 21:13:52,,1323102881,7/14/2014 21:13:29,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],diagnosis of,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 21:20:38,,1323105886,7/14/2014 21:20:19,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],confirming or excluding,n/a,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 21:45:28,,1323120990,7/14/2014 21:44:57,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Consider consulting an endocrinologist or specialist in HYPERTENSION confirming or excluding the diagnosis,MULTIFOCAL LEUKOENCEPHALOPATHY,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 22:08:31,,1323133067,7/14/2014 22:07:26,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",HYPERTENSION assist confirming excluding diagnosis of PHEOCHROMOCYTOMA,Diagnosed by Test or Drug/ Symptom,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 22:28:23,,1323145338,7/14/2014 22:27:34,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/14/2014 23:45:17,,1323182308,7/14/2014 23:44:55,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSION to assist in confirming excluding diagnosis PHEOCHROMOCYTOMA,na,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/15/2014 01:56:13,,1323278813,7/15/2014 01:55:43,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HYPERTENSION PHEOCHROMOCYTOMA,n/a,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/15/2014 03:25:34,,1323317303,7/15/2014 03:24:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],HYPERTENSION confirming or excluding PHEOCHROMOCYTOMA,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/15/2014 03:48:36,,1323326508,7/15/2014 03:48:07,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirming or excluding the diagnosis,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/15/2014 04:31:19,,1323347695,7/15/2014 04:30:41,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[SYMPTOM],[SYMPTOM],assist in confirming or excluding the diagnosis,N/A,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007850,7/15/2014 05:03:24,,1323357896,7/15/2014 05:02:50,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],na,I don't see a link,64,131,75,147,-1,RO-disease_may_have_finding,902674-FS1,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
503007851,7/14/2014 20:41:27,,1323086479,7/14/2014 20:40:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],secretory responses of to D glucose,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/14/2014 20:42:08,,1323086769,7/14/2014 20:42:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],CELLS,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/14/2014 20:58:38,,1323095408,7/14/2014 20:58:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],responses of ISLET CELLS to D glucose in model of DIABETES,Part of study,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/14/2014 21:19:49,,1323105513,7/14/2014 21:19:29,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in this experimental model of,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/14/2014 21:21:36,,1323106255,7/14/2014 21:20:57,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in this,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 01:02:48,,1323242991,7/15/2014 01:01:30,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[LOCATION] [OTHER] [MANIFESTATION] [ASSOCIATED_WITH],"[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[OTHER]",preferential the into,fds,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 02:49:20,,1323303630,7/15/2014 02:48:15,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],experimental,not applicable,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 03:15:04,,1323314088,7/15/2014 03:13:38,clixsense,1.0,14466721,CAN,ON,Hamilton,216.209.129.175,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",preferential impairment,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 03:54:49,,1323329670,7/15/2014 03:53:32,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,ISLET CELLS to D glucose in this experimental model of DIABETES,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 03:55:35,,1323330047,7/15/2014 03:55:01,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],experimental model,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 05:33:56,,1323368066,7/15/2014 05:33:22,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],partly attributable,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 05:34:49,,1323368438,7/15/2014 05:34:21,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],secretory responses,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 05:51:05,,1323373219,7/15/2014 05:49:06,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the oxidative and secretory responses of ISLET CELLS to D glucose experimental,the expriment of ISLET CELLS to D glucose in this experimental model of DIABETES,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 06:53:56,,1323391739,7/15/2014 06:52:08,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],secretory responses,n/a,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007851,7/15/2014 07:29:15,,1323408345,7/15/2014 07:28:30,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],in this model of,N/A,100,155,110,163,1,RO-disease_has_primary_anatomic_site,902036-FS1,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
503007852,7/14/2014 20:40:45,,1323086123,7/14/2014 20:40:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],OBESITY,N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 20:57:40,,1323094791,7/14/2014 20:56:07,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[SIDE_EFFECT] [IS_A] [PART_OF] [OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]
[OTHER]",SEVERE OBESITY among young men due increased persistence of OBESITY,N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 21:11:18,,1323101785,7/14/2014 21:10:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],of,N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 21:16:43,,1323104244,7/14/2014 21:16:05,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OBESITY,n/a,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 21:22:46,,1323106813,7/14/2014 21:22:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PART_OF],[PART_OF],prevalence,N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 21:47:40,,1323122642,7/14/2014 21:47:26,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",SEVERE OBESITY OBESITY,n/a,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 21:55:53,,1323126298,7/14/2014 21:55:24,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],due to an increased persistence,[CAUSES],176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 22:43:40,,1323151372,7/14/2014 22:42:20,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[CAUSES],[CAUSES],"increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/14/2014 23:38:09,,1323177196,7/14/2014 23:36:56,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],SEVERE OBESITY among young men is due to an increased persistence of OBESITY,Severe obesity basically comes from being obese in the first place,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/15/2014 00:35:36,,1323221173,7/15/2014 00:34:13,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],increased persistence of,n/a,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/15/2014 00:41:04,,1323225857,7/15/2014 00:40:40,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],prevalence of SEVERE OBESITY to OBESITY,N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/15/2014 01:12:54,,1323250157,7/15/2014 01:12:37,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES],[CAUSES],SEVERE OBESITY,dsadw,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/15/2014 01:24:08,,1323257819,7/15/2014 01:23:39,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],due to,NONE,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/15/2014 02:34:01,,1323297120,7/15/2014 02:33:39,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE OBESITY OBESITY,n/a,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007852,7/15/2014 03:21:05,,1323315874,7/15/2014 03:20:34,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],SEVERE OBESITY persistence of OBESITY,N/A,176,169,182,183,-1,RO-has_definitional_manifestation,904974-FS1,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
503007853,7/14/2014 20:56:08,,1323093961,7/14/2014 20:55:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CONTRAINDICATES],[CONTRAINDICATES],harmful for patients with,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/14/2014 21:19:19,,1323105310,7/14/2014 21:18:58,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],high intake of,n/a,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/14/2014 21:26:53,,1323108951,7/14/2014 21:26:34,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/14/2014 21:35:36,,1323113759,7/14/2014 21:34:59,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],risk,n/a,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/14/2014 21:48:44,,1323123201,7/14/2014 21:48:34,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEMOCHROMATOSIS IRON,n/a,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/14/2014 22:27:05,,1323144738,7/14/2014 22:25:40,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CONTRAINDICATES],[CONTRAINDICATES],harmful for,na,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/14/2014 22:47:26,,1323152768,7/14/2014 22:46:46,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[CAUSES],[CAUSES],high intake of harmful,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 00:41:26,,1323226094,7/15/2014 00:41:05,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],HEMOCHROMATOSIS risk for IRON overload.,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 01:11:43,,1323249405,7/15/2014 01:11:07,prodege,1.0,2145087,USA,WV,Wheeling,71.199.112.204,[CONTRAINDICATES],[CONTRAINDICATES],at risk for,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 01:26:51,,1323259625,7/15/2014 01:25:44,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CONTRAINDICATES],[CONTRAINDICATES],at risk for IRON overload.,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 01:59:39,,1323281214,7/15/2014 01:59:20,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],harmful,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 03:10:26,,1323312325,7/15/2014 03:09:35,clixsense,1.0,14466721,CAN,ON,Hamilton,216.209.129.175,[MANIFESTATION],[MANIFESTATION],iron is harmful,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 03:19:13,,1323315275,7/15/2014 03:18:48,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],harmful,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 05:13:00,,1323361041,7/15/2014 05:12:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],and others at risk for IRON overload.,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007853,7/15/2014 05:35:18,,1323368529,7/15/2014 05:34:50,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CONTRAINDICATES],[CONTRAINDICATES],at risk for IRON overload.,N/A,51,94,65,98,1,RO-contraindicated_drug,901227-FS1,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
503007854,7/14/2014 20:39:05,,1323085313,7/14/2014 20:38:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was related,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 20:57:47,,1323094882,7/14/2014 20:57:26,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],"(LEUKOPENIA in three, GRANULOCYTOPENIA in three,",Different conditions,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 20:58:05,,1323095054,7/14/2014 20:57:41,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related,n/a,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 20:58:27,,1323095305,7/14/2014 20:57:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],toxicity,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 21:20:00,,1323105594,7/14/2014 21:19:35,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 21:24:42,,1323107730,7/14/2014 21:24:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 21:48:28,,1323123058,7/14/2014 21:47:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],toxicity was related to myelosuppression.,N/a,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 22:18:29,,1323139343,7/14/2014 22:17:19,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",(LEUKOPENIA GRANULOCYTOPENIA toxicity related to myelosuppression.,symptom/associated with,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 22:33:59,,1323147629,7/14/2014 22:33:11,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related to,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 22:40:02,,1323149916,7/14/2014 22:37:26,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],and,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 23:15:56,,1323165513,7/14/2014 23:14:39,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],grade 3,different conditions,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/14/2014 23:42:57,,1323180532,7/14/2014 23:42:13,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(LEUKOPENIA in three, GRANULOCYTOPENIA in three,",na,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/15/2014 03:09:29,,1323311960,7/15/2014 03:07:58,clixsense,1.0,14466721,CAN,ON,Hamilton,216.209.129.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and grade 3,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/15/2014 03:35:40,,1323320574,7/15/2014 03:35:16,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,"(LEUKOPENIA in three, GRANULOCYTOPENIA in three,",59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007854,7/15/2014 03:52:17,,1323328365,7/15/2014 03:51:33,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related to,N/A,59,80,68,96,-1,RO-has_definitional_manifestation,904978-FS1,"Most of the grade 4 (granulocytopenia in one) and grade 3 (LEUKOPENIA in three, GRANULOCYTOPENIA in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",LEUKOPENIA,GRANULOCYTOPENIA
503007855,7/14/2014 21:22:56,,1323106887,7/14/2014 21:22:34,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/14/2014 21:25:01,,1323107911,7/14/2014 21:24:32,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,n/a,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/14/2014 21:50:36,,1323124202,7/14/2014 21:50:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/14/2014 22:20:16,,1323140529,7/14/2014 22:19:31,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],n/a,No connection between the two.,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/14/2014 22:27:32,,1323144977,7/14/2014 22:27:03,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 01:24:56,,1323258376,7/15/2014 01:24:10,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],between,NONE,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 01:58:10,,1323280127,7/15/2014 01:57:48,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,N/A,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 02:33:36,,1323296939,7/15/2014 02:32:48,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CARCINOMA IN SITU SEVERE DYSPLASIA,n/a,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 03:20:49,,1323315777,7/15/2014 03:20:35,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,N/A,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 03:29:05,,1323318241,7/15/2014 03:28:20,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 03:53:14,,1323328829,7/15/2014 03:52:18,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],significant differences,N/A,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 05:31:01,,1323367166,7/15/2014 05:30:22,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,different terms,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 06:15:11,,1323380419,7/15/2014 06:14:32,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[NONE],[NONE],N/A,N/A,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 06:23:52,,1323382845,7/15/2014 06:23:02,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between and,n/a,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007855,7/15/2014 07:24:26,,1323406574,7/15/2014 07:23:38,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],between the different lesions except between and moderate and,N/A,240,205,255,222,-1,RO-disease_has_finding,901746-FS1,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between CARCINOMA IN SITU and moderate and SEVERE DYSPLASIA,SEVERE DYSPLASIA,CARCINOMA IN SITU
503007856,7/14/2014 20:43:21,,1323087341,7/14/2014 20:43:14,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],immunogenic,n/a,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/14/2014 21:01:10,,1323096796,7/14/2014 21:00:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],RABIES RABIES VIRUS,N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/14/2014 21:12:15,,1323102241,7/14/2014 21:11:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],"virus,",N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/14/2014 21:36:28,,1323114290,7/14/2014 21:36:16,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RABIES RABIES VIRUS,n/a,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/14/2014 21:43:59,,1323119751,7/14/2014 21:43:11,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been developed by inserting,[DIAGNOSE_BY_TEST_OR_DRUG],286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/14/2014 21:52:12,,1323124891,7/14/2014 21:51:34,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[CAUSES],[CAUSES],"RABIES a recombinant vaccinia virus, RABIES VIRUS",N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/14/2014 22:02:12,,1323129216,7/14/2014 22:00:01,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],RABIES,na,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 00:52:43,,1323235106,7/15/2014 00:51:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],"a virus,",n/a,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 01:09:45,,1323248013,7/15/2014 01:09:16,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],"recombinant vaccinia virus,",N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 01:17:14,,1323253186,7/15/2014 01:15:14,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],to vaccinate against,N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 01:45:12,,1323271572,7/15/2014 01:44:29,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",RABIES RABIES VIRUS,n/a,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 01:49:34,,1323274478,7/15/2014 01:49:03,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],developed,N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 04:03:40,,1323333943,7/15/2014 04:02:59,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[PREVENTS],[PREVENTS],to vaccinate,N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 05:22:58,,1323364542,7/15/2014 05:22:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],RABIES RABIES,N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007856,7/15/2014 05:32:39,,1323367653,7/15/2014 05:31:55,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],been developed,N/A,286,103,297,109,-1,RO-has_causative_agent,903925-FS1,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
503007857,7/14/2014 20:40:28,,1323086013,7/14/2014 20:40:17,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],chromosome,n/a,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/14/2014 20:59:55,,1323096159,7/14/2014 20:59:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/14/2014 21:24:30,,1323107656,7/14/2014 21:24:16,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],deletion,n/a,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/14/2014 22:39:18,,1323149629,7/14/2014 22:38:36,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/14/2014 22:42:19,,1323150865,7/14/2014 22:41:39,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",21q marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 01:15:11,,1323251734,7/15/2014 01:14:38,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 01:49:46,,1323274615,7/15/2014 01:49:35,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 03:22:51,,1323316469,7/15/2014 03:22:37,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 04:36:13,,1323349368,7/15/2014 04:35:00,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],disorders associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 05:13:59,,1323361364,7/15/2014 05:13:34,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,n/a,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 05:16:29,,1323362324,7/15/2014 05:15:17,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,na,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 05:22:19,,1323364362,7/15/2014 05:21:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],or other myeloproliferative disorders associated with,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 05:22:26,,1323364376,7/15/2014 05:21:58,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results indicate,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 06:04:37,,1323377501,7/15/2014 06:03:58,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[NONE],[NONE],N-A,N/A,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007857,7/15/2014 06:56:04,,1323392507,7/15/2014 06:55:22,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",myeloproliferative disorders associated,n/a,200,122,213,145,-1,RO-has_manifestation,906481-FS1,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
503007858,7/14/2014 21:04:49,,1323098764,7/14/2014 21:04:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/14/2014 21:44:41,,1323120432,7/14/2014 21:44:17,instagc,1.0,18960682,GBR,"","",86.29.147.112,[NONE],[NONE],N/a,Two different conditions.,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/14/2014 22:19:29,,1323139971,7/14/2014 22:18:31,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],n/a,No connection between the two.,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/14/2014 22:20:44,,1323140833,7/14/2014 22:19:54,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],needs of family and professional carers of people,na,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/14/2014 22:22:22,,1323141958,7/14/2014 22:21:00,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,"none - they are both diseases,but don't seem to have a correlation",121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/14/2014 22:37:18,,1323148979,7/14/2014 22:36:49,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/14/2014 22:46:42,,1323152487,7/14/2014 22:45:40,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],and,N/A,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 00:41:21,,1323226055,7/15/2014 00:41:01,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,two separate conditions,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 01:08:45,,1323247314,7/15/2014 01:08:05,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,Two separate diseases.,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 01:12:33,,1323249947,7/15/2014 01:11:44,prodege,1,2145087,USA,WV,Wheeling,71.199.112.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 02:32:45,,1323296620,7/15/2014 02:31:11,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DOWN'S SYNDROME ALZHEIMER'S DISEASE,n/a,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 04:42:16,,1323351287,7/15/2014 04:41:28,gifthulk,1,20382530,CAN,ON,Hamilton,216.209.129.175,[OTHER],[OTHER],the needs of family and professional carers,N/A,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 05:07:15,,1323359116,7/15/2014 05:05:24,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[NONE],[NONE],N/A,Alzheimers  and Downs syndrome are two unrelated diseases/conditions with different causes.,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 05:11:37,,1323360619,7/15/2014 05:10:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],people with and,N/A,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007858,7/15/2014 05:25:51,,1323365436,7/15/2014 05:25:21,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,two different conditions,121,101,139,116,-1,RO-has_manifestation,906086-FS1,"In this article, the second of two parts, the needs of family and professional carers of people with DOWN'S SYNDROME and ALZHEIMER'S DISEASE are examined.",ALZHEIMER'S DISEASE,DOWN'S SYNDROME
503007859,7/14/2014 20:37:06,,1323084254,7/14/2014 20:36:59,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],LIVER LIVER,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 21:01:32,,1323096944,7/14/2014 21:01:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in the LIVER,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 21:14:36,,1323103263,7/14/2014 21:13:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in the,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 21:15:39,,1323103789,7/14/2014 21:15:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],LIVER LIVER FAILURE;,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 21:24:14,,1323107533,7/14/2014 21:23:57,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],in the,n/a,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 21:51:15,,1323124516,7/14/2014 21:50:35,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],toxic levels in the LIVER causing LIVER FAILURE;,causes,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 21:51:44,,1323124745,7/14/2014 21:51:11,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],causing,n/a,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 22:51:49,,1323154729,7/14/2014 22:51:24,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],causing,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 22:54:42,,1323156038,7/14/2014 22:54:27,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],causing,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/14/2014 23:28:57,,1323172031,7/14/2014 23:28:00,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS],[TREATS],liver transplant becomes necessary.,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/15/2014 00:37:47,,1323223039,7/15/2014 00:37:23,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],toxic levels in the LIVER causing LIVER FAILURE;,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/15/2014 01:51:07,,1323275556,7/15/2014 01:50:47,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],in the,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/15/2014 03:12:29,,1323313107,7/15/2014 03:10:52,clixsense,1,14466721,CAN,ON,Hamilton,216.209.129.175,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]",toxic levels in the causing,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/15/2014 03:20:33,,1323315707,7/15/2014 03:20:18,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[LOCATION],[LOCATION],in the,N/A,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007859,7/15/2014 03:46:50,,1323325734,7/15/2014 03:45:49,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE,60,74,64,87,1,RO-disease_has_primary_anatomic_site,902160-FS1,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
503007860,7/14/2014 20:40:53,,1323086205,7/14/2014 20:40:46,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],associated,n/a,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/14/2014 20:42:00,,1323086718,7/14/2014 20:41:31,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/14/2014 21:10:52,,1323101617,7/14/2014 21:10:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/14/2014 21:49:08,,1323123461,7/14/2014 21:48:59,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOSIS PV,n/a,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/14/2014 22:24:39,,1323143360,7/14/2014 22:24:03,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],THROMBOSIS in PV,manifestation,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/14/2014 23:40:27,,1323178726,7/14/2014 23:38:58,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[SYMPTOM],[SYMPTOM],risk of recurrent THROMBOSIS in PV,na,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 00:31:23,,1323217642,7/15/2014 00:31:01,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],recurrent THROMBOSIS in PV,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 00:54:16,,1323236256,7/15/2014 00:52:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,n/a,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 02:48:13,,1323303040,7/15/2014 02:47:36,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,not applicable,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 04:29:21,,1323346931,7/15/2014 04:28:43,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[SYMPTOM],[SYMPTOM],high risk of recurrent in,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 05:09:28,,1323359863,7/15/2014 05:09:05,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],recurrent THROMBOSIS in PV,n/a,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 05:38:38,,1323369383,7/15/2014 05:38:14,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],in,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 06:14:04,,1323380142,7/15/2014 06:13:09,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly associated,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 07:25:45,,1323407060,7/15/2014 07:24:27,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],high risk of recurrent in,N/A,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007860,7/15/2014 07:50:50,,1323415834,7/15/2014 07:49:46,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],in,n/a,117,131,126,133,1,RO-has_manifestation,906362-FS1,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
503007861,7/14/2014 20:44:22,,1323087885,7/14/2014 20:44:15,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],gallbladder.,n/a,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/14/2014 21:36:42,,1323114397,7/14/2014 21:36:29,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INTESTINAL METAPLASIA INTESTINAL TYPE ADENOCARCINOMA,n/a,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/14/2014 21:58:45,,1323127496,7/14/2014 21:58:01,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],also been reported in the gallbladder.,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/14/2014 22:49:00,,1323153441,7/14/2014 22:48:25,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 01:10:28,,1323248551,7/15/2014 01:08:44,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[MANIFESTATION] [OTHER],"[MANIFESTATION]
[OTHER]",also been reported,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 01:52:52,,1323276712,7/15/2014 01:52:33,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 02:15:06,,1323289304,7/15/2014 02:13:31,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INTESTINAL METAPLASIA INTESTINAL TYPE ADENOCARCINOMA,n/a,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 04:00:40,,1323332605,7/15/2014 04:00:03,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[LOCATION],[LOCATION],"stomach,",N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 04:46:53,,1323352423,7/15/2014 04:45:25,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],features of intestinal type adenocarcinoma,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 05:10:43,,1323360306,7/15/2014 05:10:19,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA,n/a,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 05:14:47,,1323361689,7/15/2014 05:14:17,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],reported in the gallbladder.,na,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 05:16:21,,1323362290,7/15/2014 05:15:54,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 05:33:22,,1323367900,7/15/2014 05:32:55,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,different conditions,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 05:39:26,,1323369599,7/15/2014 05:38:56,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],well documented,N/A,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007861,7/15/2014 06:22:06,,1323382356,7/15/2014 06:21:36,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[LOCATION],[LOCATION],has also been reported the gallbladder.,INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.,111,137,131,167,-1,RO-disease_has_finding,901591-FS1,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
503007862,7/14/2014 21:09:17,,1323100797,7/14/2014 21:08:08,clixsense,1.0,15189335,GBR,H9,London,188.29.164.19,[LOCATION],[LOCATION],reaches the,Na,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:09:56,,1323101166,7/14/2014 21:09:37,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],reaches,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:23:14,,1323107021,7/14/2014 21:22:57,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],reaches the,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:23:58,,1323107420,7/14/2014 21:23:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],causes,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:26:33,,1323108789,7/14/2014 21:26:19,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:26:50,,1323108932,7/14/2014 21:26:34,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],causes,n/a,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:45:22,,1323120918,7/14/2014 21:44:53,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",causes progressive,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:45:34,,1323121074,7/14/2014 21:45:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],virus reaches the,N/a,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 21:55:09,,1323126059,7/14/2014 21:54:48,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 22:02:23,,1323129307,7/14/2014 22:01:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY,Location,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 22:06:58,,1323132095,7/14/2014 22:06:09,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],reaches the,n/a,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 22:41:38,,1323150597,7/14/2014 22:41:02,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[LOCATION],[LOCATION],reaches the,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 23:02:18,,1323159920,7/14/2014 23:01:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],causes progressive,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/14/2014 23:17:30,,1323166222,7/14/2014 23:16:14,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY,The brain is related to multifocal because the brain can cause multifocal,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007862,7/15/2014 00:26:52,,1323213778,7/15/2014 00:25:49,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],BRAIN causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY,N/A,33,62,37,92,1,RO-disease_has_primary_anatomic_site,902284-FS1,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
503007863,7/14/2014 20:38:20,,1323084916,7/14/2014 20:38:00,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],caused by,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 20:39:05,,1323085316,7/14/2014 20:38:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 21:16:56,,1323104321,7/14/2014 21:16:43,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],caused,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 21:27:52,,1323109487,7/14/2014 21:27:38,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],caused,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 21:46:59,,1323122244,7/14/2014 21:46:38,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],whether it is caused by,N/a,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 21:47:24,,1323122483,7/14/2014 21:47:04,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",END STAGE LIVER DISEASE ALCOHOLIC CIRRHOSIS,n/a,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 21:54:31,,1323125841,7/14/2014 21:53:45,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],END STAGE LIVER DISEASE caused ALCOHOLIC CIRRHOSIS,causes,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 22:38:01,,1323149185,7/14/2014 22:37:19,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[CAUSES] [LOCATION],"[CAUSES]
[LOCATION]","The surgical implantation of a donor liver into patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 22:47:46,,1323152935,7/14/2014 22:47:17,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],caused by,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 23:30:52,,1323173025,7/14/2014 23:29:52,gifthulk,1,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],END STAGE LIVER DISEASE caused by ALCOHOLIC CIRRHOSIS,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/14/2014 23:41:20,,1323179391,7/14/2014 23:40:27,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],caused by ALCOHOLIC CIRRHOSIS chronic,n/a,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/15/2014 00:41:41,,1323226265,7/15/2014 00:41:22,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],caused by,n/a,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/15/2014 01:48:14,,1323273541,7/15/2014 01:47:16,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],END STAGE LIVER DISEASE ALCOHOLIC CIRRHOSIS,n/a,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/15/2014 03:49:29,,1323326986,7/15/2014 03:46:52,elite,1.0,27788262,USA,"","",172.129.7.231,[SYMPTOM],[SYMPTOM],caused by,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007863,7/15/2014 04:32:51,,1323348277,7/15/2014 04:32:15,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[MANIFESTATION],[MANIFESTATION],caused by,N/A,104,152,126,171,1,RO-disease_has_primary_anatomic_site,902320-FS1,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
503007864,7/14/2014 20:37:59,,1323084717,7/14/2014 20:37:49,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],FALLOPIAN TUBE INFECTION FALLOPIAN TUBES,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 20:42:46,,1323087027,7/14/2014 20:42:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],microbial,n/a,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 21:01:02,,1323096739,7/14/2014 21:00:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],predisposed,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 21:47:07,,1323122313,7/14/2014 21:46:34,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],may have predisposed,[CAUSES],64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 21:51:04,,1323124444,7/14/2014 21:50:41,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],FALLOPIAN FALLOPIAN,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 22:24:02,,1323143035,7/14/2014 22:23:14,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],FALLOPIAN TUBE INFECTION predisposed FALLOPIAN TUBES,manifestation,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 22:54:05,,1323155820,7/14/2014 22:53:48,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],predisposed the,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/14/2014 22:57:16,,1323157133,7/14/2014 22:56:41,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],The parasitic may have predisposed,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 00:24:41,,1323212032,7/15/2014 00:24:10,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],FALLOPIAN TUBE INFECTION predisposed the FALLOPIAN TUBES,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 00:41:01,,1323225790,7/15/2014 00:40:31,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],parasitic FALLOPIAN TUBE INFECTION,n/a,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 01:07:09,,1323246244,7/15/2014 01:06:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],tuboovarian abscess.,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 02:15:33,,1323289472,7/15/2014 02:15:08,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FALLOPIAN TUBE INFECTION FALLOPIAN TUBES,n/a,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 05:19:44,,1323363435,7/15/2014 05:19:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],FALLOPIAN TUBE INFECTION,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 05:32:00,,1323367457,7/15/2014 05:31:35,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],may have predisposed the,N/A,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007864,7/15/2014 06:19:05,,1323381490,7/15/2014 06:18:24,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],may have predisposed the to a microbial tuboovarian abscess.,FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,64,14,78,38,1,RO-has_finding_site,905312-FS1,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
503007865,7/14/2014 20:57:41,,1323094805,7/14/2014 20:57:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],due to,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 21:01:04,,1323096749,7/14/2014 21:00:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",caused by associated with,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 21:01:38,,1323096990,7/14/2014 20:58:58,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[PART_OF] [OTHER] [IS_A] [ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]
[OTHER]",arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 21:11:55,,1323102085,7/14/2014 21:11:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],due to,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 21:28:09,,1323109604,7/14/2014 21:27:54,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 21:34:59,,1323113414,7/14/2014 21:34:44,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 21:54:30,,1323125838,7/14/2014 21:54:03,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[CAUSES],[CAUSES],due to,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 22:36:48,,1323148809,7/14/2014 22:36:15,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],abnormal biomechanics were associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/14/2014 23:16:13,,1323165645,7/14/2014 23:15:33,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",were caused by or associated with,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/15/2014 01:08:20,,1323247018,7/15/2014 01:08:04,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[LOCATION],[LOCATION],biomechanics,dwad,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/15/2014 01:15:14,,1323251801,7/15/2014 01:14:29,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",due to,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/15/2014 02:10:58,,1323287468,7/15/2014 02:10:25,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],ARTHROSIS OVERUSED JOINTS,n/a,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/15/2014 03:10:01,,1323312127,7/15/2014 03:08:20,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],ARTHROSIS due OVERUSED JOINTS,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/15/2014 03:49:02,,1323326769,7/15/2014 03:48:36,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],caused by or associated with,N/A,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007865,7/15/2014 05:20:08,,1323363600,7/15/2014 05:19:35,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],due to advanced age,na,116,83,130,92,1,RO-disease_has_primary_anatomic_site,902442-FS1,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
503007866,7/14/2014 20:42:29,,1323086919,7/14/2014 20:42:22,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],flushing;,n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 20:45:37,,1323088452,7/14/2014 20:45:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN or HIVES;,N/A,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 21:08:34,,1323100523,7/14/2014 21:08:08,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(e.g.,",N/A,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 21:13:17,,1323102625,7/14/2014 21:12:59,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],Involvement of the SKIN,N/A,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 21:15:28,,1323103680,7/14/2014 21:14:49,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],Involvement of the SKIN,n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 21:26:17,,1323108644,7/14/2014 21:26:05,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],"(e.g.,",n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 21:32:40,,1323112138,7/14/2014 21:32:15,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[LOCATION],[LOCATION],Involvement of,n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 21:51:41,,1323124687,7/14/2014 21:51:26,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],Involvement of the,N/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 22:01:09,,1323128706,7/14/2014 21:59:40,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],Involvement of the,n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 22:48:12,,1323153129,7/14/2014 22:47:31,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[LOCATION],[LOCATION],Involvement of,N/A,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/14/2014 23:18:54,,1323167431,7/14/2014 23:15:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],"Involvement (e.g.,",n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/15/2014 00:31:00,,1323217341,7/15/2014 00:30:13,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],"SKIN or mucosal tissue (e.g., generalized HIVES;",N/A,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/15/2014 01:04:49,,1323244468,7/15/2014 01:04:25,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[LOCATION] [CONTRAINDICATES] [SYMPTOM],"[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]",itching,dsa,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/15/2014 02:19:29,,1323291324,7/15/2014 02:18:49,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",SKIN HIVES;,n/a,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007866,7/15/2014 03:24:44,,1323317086,7/15/2014 03:24:15,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],Involvement of SKIN generalized HIVES;,N/A,19,61,22,66,1,RO-has_finding_site,905314-FS1,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
503007867,7/14/2014 20:47:02,,1323089212,7/14/2014 20:44:44,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[NONE],[NONE],N/A,The statement is questioning if there is any relationship at all.,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 21:18:06,,1323104830,7/14/2014 21:17:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[NONE],[NONE],n/a,highlighted terms don't make sense,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 21:22:05,,1323106481,7/14/2014 21:21:43,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS,N/A,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 21:53:33,,1323125478,7/14/2014 21:52:46,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[NONE],[NONE],N/A,No words suggest a relationship.,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 22:18:34,,1323139418,7/14/2014 22:17:30,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[NONE],[NONE],na,doesnt make any sense,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 22:24:42,,1323143389,7/14/2014 22:23:40,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],two themes:,na,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 22:59:07,,1323158126,7/14/2014 22:58:33,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],RECOGNITION OF SITE OF origin,N/A,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 23:14:38,,1323164972,7/14/2014 23:13:07,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS Of,n/a,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/14/2014 23:43:36,,1323181053,7/14/2014 23:42:58,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[NONE],[NONE],N/A,"I could not tell, it seemed like a load of gibberish",132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/15/2014 01:08:04,,1323246874,7/15/2014 01:07:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS,N/A,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/15/2014 01:50:08,,1323274839,7/15/2014 01:49:47,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS,N/A,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/15/2014 01:58:21,,1323280275,7/15/2014 01:57:42,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS QRS TACHYCARDIAS AND RECOGNITION OF THE SITE OF,n/a,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/15/2014 02:29:05,,1323295135,7/15/2014 02:28:31,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS Of QRS TACHYCARDIAS AND RECOGNITION OF THE SITE OF,n/a,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/15/2014 03:48:05,,1323326273,7/15/2014 03:47:04,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],concerns the electrocardiogram in ventricular,N/A,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007867,7/15/2014 04:26:11,,1323345461,7/15/2014 04:24:22,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[PART_OF],[PART_OF],tachycardias with two themes:,N/A,132,99,174,113,-1,RO-has_definitional_manifestation,904502-FS1,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
503007868,7/14/2014 20:36:58,,1323084148,7/14/2014 20:36:51,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SKIN,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 20:54:46,,1323093269,7/14/2014 20:54:15,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by deposits of the SKIN,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 21:16:39,,1323104203,7/14/2014 21:16:00,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],of the,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 21:23:04,,1323106943,7/14/2014 21:22:35,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized,n/a,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 21:40:01,,1323116554,7/14/2014 21:39:29,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],along the basal zone of the SKIN,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 22:17:32,,1323138687,7/14/2014 22:16:58,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],deposits along the basal zone of the,n/a,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 22:29:26,,1323145755,7/14/2014 22:28:24,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION] [IS_A],"[LOCATION]
[IS_A]","BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes,",N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 22:38:31,,1323149381,7/14/2014 22:37:53,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[LOCATION],[LOCATION],along the basal zone of the,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 22:48:23,,1323153174,7/14/2014 22:47:44,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],along the basal zone,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/14/2014 23:29:40,,1323172378,7/14/2014 23:28:58,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[IS_A],[IS_A],BENIGN MUCOUS MEMBRANE PEMPHIGOID is,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/15/2014 02:55:16,,1323306035,7/15/2014 02:54:42,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],characterized by along the basal zone of,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/15/2014 03:24:33,,1323317024,7/15/2014 03:24:17,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[LOCATION],[LOCATION],basal zone,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/15/2014 03:27:52,,1323317979,7/15/2014 03:27:21,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) along the SKIN,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/15/2014 04:44:25,,1323351827,7/15/2014 04:43:46,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[LOCATION] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]",characterized by,N/A,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007868,7/15/2014 05:08:47,,1323359596,7/15/2014 05:08:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],characterized by immunoglobulin deposits along the basal zone,n/a,113,0,116,33,1,RO-disease_has_primary_anatomic_site,902325-FS1,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
503007869,7/14/2014 20:43:35,,1323087509,7/14/2014 20:41:58,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],was shown,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 21:14:14,,1323103041,7/14/2014 21:13:55,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],DIC,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 21:20:39,,1323105878,7/14/2014 21:20:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],DIC,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 21:37:44,,1323114979,7/14/2014 21:37:02,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",showing resolution of,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 21:42:57,,1323118878,7/14/2014 21:42:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA,n/a,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 21:53:02,,1323125275,7/14/2014 21:51:57,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],showing resolution of,N/a,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 22:29:41,,1323145883,7/14/2014 22:28:59,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[IS_A],[IS_A],DIC SECONDARY TO ACUTE DIC,na,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/14/2014 23:43:55,,1323181374,7/14/2014 23:43:21,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA,n/a,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 00:40:39,,1323225516,7/15/2014 00:39:44,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 01:08:43,,1323247256,7/15/2014 01:06:51,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",resolution of,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 01:55:10,,1323278155,7/15/2014 01:54:43,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],with,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 03:22:36,,1323316382,7/15/2014 03:21:43,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],showing resolution,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 05:04:45,,1323358297,7/15/2014 05:04:21,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showing resolution of DIC,n/a,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 05:27:11,,1323365822,7/15/2014 05:26:31,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showing resolution,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007869,7/15/2014 05:31:18,,1323367289,7/15/2014 05:29:36,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",controlled trial fewer bleeding,N/A,129,129,131,174,-1,RO-disease_may_have_finding,902964-FS1,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
503007870,7/14/2014 20:43:30,,1323087448,7/14/2014 20:43:22,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],treatment,n/a,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/14/2014 21:46:01,,1323121477,7/14/2014 21:44:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST OPIOID,n/a,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/14/2014 21:46:32,,1323121871,7/14/2014 21:46:01,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",investigated as a treatment for,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/14/2014 22:06:08,,1323131571,7/14/2014 22:05:34,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],is being investigated as a treatment for,n/a,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/14/2014 22:14:23,,1323136774,7/14/2014 22:11:43,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],treatment,na,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/14/2014 22:28:53,,1323145523,7/14/2014 22:28:03,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[TREATS],[TREATS],treatment,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/14/2014 23:37:01,,1323176600,7/14/2014 23:36:27,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],as a treatment,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 00:54:32,,1323236418,7/15/2014 00:54:18,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment for,n/a,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 01:16:20,,1323252523,7/15/2014 01:15:19,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 02:25:28,,1323293767,7/15/2014 02:24:57,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST OPIOID DEPENDENCE,n/a,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 03:26:22,,1323317526,7/15/2014 03:26:12,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treatment,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 03:49:17,,1323326887,7/15/2014 03:49:03,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],investigated as a treatment,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 05:13:41,,1323361298,7/15/2014 05:13:01,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is being investigated as a treatment for,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 05:33:44,,1323368015,7/15/2014 05:33:23,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[TREATS],[TREATS],is being investigated as a treatment,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007870,7/15/2014 06:15:05,,1323380386,7/15/2014 06:14:05,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],investigated as a treatment,N/A,0,89,46,106,-1,RO-has_causative_agent,903537-FS1,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
503007871,7/14/2014 21:20:36,,1323105867,7/14/2014 21:19:56,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],of THE,n/a,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/14/2014 21:29:06,,1323110232,7/14/2014 21:28:48,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],of,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/14/2014 21:34:09,,1323112937,7/14/2014 21:33:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has performed,[DIAGNOSE_BY_TEST_OR_DRUG],82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/14/2014 21:43:42,,1323119526,7/14/2014 21:43:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]",of,n/a,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/14/2014 21:56:02,,1323126331,7/14/2014 21:55:48,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],of,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/14/2014 22:07:43,,1323132572,7/14/2014 22:06:59,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],of,n/a,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/14/2014 22:41:24,,1323150434,7/14/2014 22:40:23,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],of THE,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 01:15:28,,1323251959,7/15/2014 01:15:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],of,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 01:29:41,,1323261421,7/15/2014 01:29:02,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],of,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 02:22:43,,1323292662,7/15/2014 02:21:58,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ARTHRITIS THE BASAL JOINT OF THE THUMB,n/a,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 03:26:01,,1323317428,7/15/2014 03:25:34,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],ARTHRITIS of THE BASAL JOINT OF THE THUMB,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 05:10:53,,1323360406,7/15/2014 05:10:02,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],ARTHRITIS of,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 05:11:03,,1323360458,7/15/2014 05:10:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],for ARTHRITIS of THE BASAL JOINT OF THE THUMB,n/a,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 05:28:24,,1323366273,7/15/2014 05:28:02,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],of,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007871,7/15/2014 05:40:10,,1323369871,7/15/2014 05:39:27,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],author has performed,N/A,82,69,109,78,1,RO-disease_has_primary_anatomic_site,902328-FS1,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
503007872,7/14/2014 20:44:40,,1323088019,7/14/2014 20:44:27,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],care,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 21:01:56,,1323097167,7/14/2014 21:01:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],MELANOMA,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 21:16:50,,1323104302,7/14/2014 21:16:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],is considered as standard of care for the staging of,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 21:23:24,,1323107175,7/14/2014 21:23:03,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PREVENTS],[PREVENTS],standard of care,n/a,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 21:40:08,,1323116611,7/14/2014 21:39:17,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",is considered as standard of care,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 21:54:01,,1323125676,7/14/2014 21:53:34,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],depth of the staging of,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 22:16:57,,1323138301,7/14/2014 22:15:54,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for the staging of,n/a,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 22:34:14,,1323147770,7/14/2014 22:32:15,neodev,1.0,20929875,USA,MA,Brighton,71.174.178.100,[TREATS],[TREATS],depth PRIMARY MELANOMA is considered standard of care for CUTANEOUS MELANOMA,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/14/2014 22:44:18,,1323151597,7/14/2014 22:43:42,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/15/2014 01:04:19,,1323244075,7/15/2014 01:03:44,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],is considered,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/15/2014 04:33:57,,1323348619,7/15/2014 04:32:57,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[IS_A],[IS_A],Breslow depth of the,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/15/2014 05:10:42,,1323360294,7/15/2014 05:10:03,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],standard staging,na,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/15/2014 05:37:27,,1323369039,7/15/2014 05:36:49,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],lymph node biopsy,N/A,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/15/2014 06:12:25,,1323379663,7/15/2014 06:11:13,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[LOCATION],[LOCATION],sentinel lymph node biopsy,PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007872,7/15/2014 06:55:20,,1323392268,7/15/2014 06:54:49,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],standard of care,n/a,38,135,53,153,-1,RO-has_manifestation,906492-FS1,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
503007873,7/14/2014 20:43:50,,1323087626,7/14/2014 20:43:40,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],prevention,n/a,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 20:48:53,,1323090141,7/14/2014 20:47:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],prevention for,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 20:58:26,,1323095280,7/14/2014 20:58:07,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[PREVENTS],[PREVENTS],prevention,n/a,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 21:18:18,,1323104895,7/14/2014 21:17:38,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],important PATHOGENESIS,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 21:22:35,,1323106732,7/14/2014 21:21:54,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],important PATHOGENESIS,n/a,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 21:25:00,,1323107900,7/14/2014 21:24:44,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PART_OF],[PART_OF],is believed,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 21:40:42,,1323117164,7/14/2014 21:40:02,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],heal,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/14/2014 21:48:52,,1323123291,7/14/2014 21:48:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],is believed as one of the important,N/a,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 01:03:59,,1323243883,7/15/2014 01:03:34,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES],[CAUSES],PATHOGENESIS,dsasda,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 01:14:36,,1323251369,7/15/2014 01:13:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],important PATHOGENESIS,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 03:45:06,,1323324938,7/15/2014 03:43:08,elite,1.0,27788262,USA,"","",172.129.7.231,[IS_A],[IS_A],is believed as one,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 03:57:30,,1323331038,7/15/2014 03:56:45,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],believed as one of the important,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 04:07:47,,1323335887,7/15/2014 04:05:44,neodev,1.0,20929875,USA,MA,Boston,96.233.17.112,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",REFLUX TO THE STOMACH believed as one of important PATHOGENESIS OF RESIDUAL,N/A,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 05:08:25,,1323359524,7/15/2014 05:07:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],believed as one of the important,n/a,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007873,7/15/2014 06:16:49,,1323380849,7/15/2014 06:16:13,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],is believed as one of the important,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS,5,63,25,97,1,RO-disease_has_primary_anatomic_site,902170-FS1,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
503007874,7/14/2014 21:18:37,,1323105025,7/14/2014 21:18:07,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",principal symptoms were LOCAL PAIN NEURALGIA SYNDROME,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/14/2014 21:28:12,,1323109655,7/14/2014 21:27:57,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],symptoms were,n/a,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/14/2014 21:44:56,,1323120600,7/14/2014 21:42:00,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],principal symptoms LOCAL PAIN NEURALGIA SYNDROME,MULTIFOCAL LEUKOENCEPHALOPATHY,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/14/2014 21:54:46,,1323125972,7/14/2014 21:53:58,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]","The principal symptoms were in 8 patients,",[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG],28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/14/2014 22:36:44,,1323148726,7/14/2014 22:35:52,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[OTHER],[OTHER],symptoms were,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/14/2014 22:55:03,,1323156149,7/14/2014 22:54:25,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],principal symptoms were,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 00:25:48,,1323212857,7/15/2014 00:24:42,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",symptoms were LOCAL PAIN NEURALGIA SYNDROME,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 01:05:49,,1323245243,7/15/2014 01:05:31,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES],[CAUSES],LOCAL PAIN,dsadds,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 01:20:07,,1323255117,7/15/2014 01:19:36,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[SYMPTOM],[SYMPTOM],symptoms,NONE,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 01:22:22,,1323256587,7/15/2014 01:21:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],principal symptoms were,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 03:25:12,,1323317198,7/15/2014 03:24:53,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 03:53:30,,1323328956,7/15/2014 03:52:46,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,"LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 04:45:17,,1323352048,7/15/2014 04:44:31,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",symptoms,N/A,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 05:11:23,,1323360568,7/15/2014 05:11:04,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,just another random symptom,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007874,7/15/2014 05:13:15,,1323361155,7/15/2014 05:12:47,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],symptoms,na,28,54,37,72,-1,RO-has_definitional_manifestation,904590-FS1,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
503007875,7/14/2014 20:40:07,,1323085834,7/14/2014 20:39:53,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],subclinical,n/a,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 20:54:59,,1323093379,7/14/2014 20:54:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],used in the treatment of,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 20:57:23,,1323094636,7/14/2014 20:57:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 21:14:36,,1323103250,7/14/2014 21:14:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],was used in the treatment of,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 21:20:17,,1323105754,7/14/2014 21:20:01,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],used in the treatment,n/a,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 21:23:38,,1323107254,7/14/2014 21:23:06,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],treatment,n/a,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 21:53:21,,1323125380,7/14/2014 21:53:04,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],was used in the treatment,N/a,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 22:05:33,,1323131173,7/14/2014 22:04:51,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],was used in the treatment,n/a,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 22:33:40,,1323147467,7/14/2014 22:33:03,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],used in the treatment of,na,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 23:19:05,,1323167523,7/14/2014 23:17:30,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS],[TREATS],ORAL ANTIFUNGAL KETOCONAZOLE) was used treatment of CUTANEOUS OR PULMONARY,they are related because you need oralantifungal to treat oral cutaneous,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/14/2014 23:35:22,,1323175582,7/14/2014 23:34:54,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[TREATS],[TREATS],an ORAL ANTIFUNGAL (EG KETOCONAZOLE) used in treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS,na,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/15/2014 00:32:16,,1323218359,7/15/2014 00:31:23,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",ORAL ANTIFUNGAL (EG KETOCONAZOLE) used treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/15/2014 01:41:59,,1323269485,7/15/2014 01:41:39,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],used in the treatment of,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/15/2014 03:23:27,,1323316736,7/15/2014 03:22:42,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],ORAL ANTIFUNGAL (EG KETOCONAZOLE) treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007875,7/15/2014 03:26:11,,1323317484,7/15/2014 03:26:00,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treatment,N/A,115,52,150,85,1,RO-may_treat,907862-FS1,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
503007876,7/14/2014 20:44:30,,1323087946,7/14/2014 20:44:24,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],suspected,n/a,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 20:56:00,,1323093869,7/14/2014 20:55:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],is not suspected,N/A,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 21:50:00,,1323123926,7/14/2014 21:49:35,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CONTRAINDICATES],[CONTRAINDICATES],is usually not suspected,N/a,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 21:50:01,,1323123927,7/14/2014 21:49:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOUS INVOLVEMENT OF PITUITARY PITUITARY ADENOMAS,n/a,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 22:21:18,,1323141231,7/14/2014 22:20:18,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],n/a,rare and not suspected.,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 22:33:01,,1323147252,7/14/2014 22:32:36,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[OTHER],[OTHER],usually not suspected,na,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 22:40:57,,1323150270,7/14/2014 22:39:22,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[OTHER],[OTHER],is rare usually not suspected with,N/A,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/14/2014 23:38:34,,1323177460,7/14/2014 23:38:10,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[IS_A],[IS_A],TUBERCULOUS INVOLVEMENT OF PITUITARY is,n/a,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 01:03:11,,1323243284,7/15/2014 01:02:51,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[CAUSES] [CONTRAINDICATES],"[CAUSES]
[CONTRAINDICATES]",PITUITARY,fesfsd,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 01:19:38,,1323254756,7/15/2014 01:18:42,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],usually not suspected,N/A,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 01:57:36,,1323279761,7/15/2014 01:57:00,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],TUBERCULOUS INVOLVEMENT OF PITUITARY PITUITARY ADENOMAS,n/a,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 02:21:54,,1323292356,7/15/2014 02:21:13,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],TUBERCULOUS INVOLVEMENT OF PITUITARY PITUITARY ADENOMAS,n/a,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 02:51:25,,1323304580,7/15/2014 02:50:59,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],dealing with,not applicable,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 03:19:20,,1323315298,7/15/2014 03:18:13,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],TUBERCULOUS INVOLVEMENT OF PITUITARY is not suspected with PITUITARY ADENOMAS,N/A,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007876,7/15/2014 05:05:48,,1323358617,7/15/2014 05:04:40,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],not suspected,N/A,0,103,35,121,1,RO-has_finding_site,905046-FS1,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
503007877,7/14/2014 20:44:12,,1323087825,7/14/2014 20:43:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],Treatment by,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 20:44:44,,1323088056,7/14/2014 20:43:52,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[TREATS],[TREATS],Treatment of POLYCYTHAEMIA VERA by BUSULPHAN:,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 21:17:48,,1323104654,7/14/2014 21:16:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[OTHER],[OTHER],Treatment of by radiophosphorus or BUSULPHAN:,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 21:21:11,,1323106076,7/14/2014 21:20:57,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],Treatment,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 21:23:40,,1323107282,7/14/2014 21:23:26,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],Treatment of by,n/a,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 21:29:01,,1323110231,7/14/2014 21:28:46,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],Treatment,n/a,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 21:32:58,,1323112336,7/14/2014 21:31:42,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],Treatment,na,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 21:39:15,,1323115996,7/14/2014 21:38:37,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Treatment of by radiophosphorus,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 22:50:51,,1323154239,7/14/2014 22:50:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],randomized trial.,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/14/2014 23:28:21,,1323171741,7/14/2014 23:27:49,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],Treatment of POLYCYTHAEMIA VERA by BUSULPHAN:,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/15/2014 01:06:11,,1323245511,7/15/2014 01:05:53,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,[LOCATION] [ASSOCIATED_WITH] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]",radiophosphorus,dsasd,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/15/2014 02:30:09,,1323295600,7/15/2014 02:29:06,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],POLYCYTHAEMIA VERA BUSULPHAN:,n/a,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/15/2014 05:28:32,,1323366291,7/15/2014 05:27:36,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Treatment trial.,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/15/2014 05:36:26,,1323368778,7/15/2014 05:36:05,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],Treatment of,N/A,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007877,7/15/2014 06:21:34,,1323382182,7/15/2014 06:21:06,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[TREATS],[TREATS],Treatment of,Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN,17,58,34,67,1,RO-may_treat,907742-FS1,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
503007878,7/14/2014 20:37:53,,1323084669,7/14/2014 20:36:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],lasted,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 20:47:30,,1323089419,7/14/2014 20:47:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIARRHEA and DYSENTERY,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 20:55:35,,1323093655,7/14/2014 20:55:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],episode,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 21:19:33,,1323105414,7/14/2014 21:19:20,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 21:45:59,,1323121448,7/14/2014 21:45:25,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],lasted a mean,[DIAGNOSE_BY_TEST_OR_DRUG],16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 21:48:02,,1323122838,7/14/2014 21:47:22,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[NONE],[NONE],N/A,"Separate things, sentence only says days for each, nothing else.",16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 22:37:25,,1323149028,7/14/2014 22:36:29,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],and those of,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/14/2014 22:44:48,,1323151771,7/14/2014 22:43:46,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 03:17:29,,1323314749,7/15/2014 03:17:11,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],lasted,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 03:20:00,,1323315525,7/15/2014 03:19:20,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],"DIARRHEA lasted 3 d, those of DYSENTERY",N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 03:35:14,,1323320341,7/15/2014 03:34:42,elite,1.0,27788262,USA,"","",172.129.7.231,[NONE],[NONE],N/A,"DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 03:54:42,,1323329584,7/15/2014 03:53:36,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[ASSOCIATED_WITH],[ASSOCIATED_WITH],lasted,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 05:08:11,,1323359410,7/15/2014 05:07:41,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],lasted,na,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 05:14:13,,1323361464,7/15/2014 05:13:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007878,7/15/2014 05:35:38,,1323368569,7/15/2014 05:35:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],"episode mean of 3 d,",N/A,16,60,23,69,-1,RO-has_definitional_manifestation,904873-FS1,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
503007879,7/14/2014 20:39:48,,1323085711,7/14/2014 20:39:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/14/2014 20:57:20,,1323094606,7/14/2014 20:56:45,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/14/2014 21:08:40,,1323100566,7/14/2014 21:08:01,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/14/2014 21:21:55,,1323106409,7/14/2014 21:21:44,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/14/2014 21:49:47,,1323123832,7/14/2014 21:49:21,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/14/2014 21:51:57,,1323124797,7/14/2014 21:51:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including that associated with,N/a,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/14/2014 22:30:41,,1323146255,7/14/2014 22:30:11,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 00:52:58,,1323235305,7/15/2014 00:52:43,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],that associated with,n/a,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 01:14:16,,1323251145,7/15/2014 01:13:31,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,none,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 03:18:47,,1323315173,7/15/2014 03:18:34,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 03:26:27,,1323317556,7/15/2014 03:26:02,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],HYPERTENSION associated with PHEOCHROMOCYTOMA,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 03:59:23,,1323332025,7/15/2014 03:58:52,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 04:21:42,,1323343108,7/15/2014 04:21:01,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[SYMPTOM],[SYMPTOM],associated with hyperthyroidism,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 05:03:19,,1323357881,7/15/2014 05:02:50,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,na,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007879,7/15/2014 05:26:30,,1323365636,7/15/2014 05:25:52,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,20,83,31,99,1,RO-disease_may_have_finding,902850-FS1,"127 ,   a ?  Severe HYPERTENSION including that associated with hyperthyroidism or PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
503007880,7/14/2014 20:42:13,,1323086815,7/14/2014 20:42:05,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],direct,n/a,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 21:02:46,,1323097601,7/14/2014 21:02:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SIDE_EFFECT],[SIDE_EFFECT],side effect,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 21:36:05,,1323114053,7/14/2014 21:35:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NAUSEA AND VOMITING EFFECT ON THE VOMITING CENTER,n/a,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 21:55:20,,1323126137,7/14/2014 21:54:48,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],due to direct central,[CAUSES],83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 22:04:05,,1323130258,7/14/2014 22:03:22,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],due to direct central,n/a,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 22:08:44,,1323133190,7/14/2014 22:07:11,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION] [CAUSES],"[CAUSES]
[LOCATION]",direct central brain.,na,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 22:45:43,,1323152108,7/14/2014 22:44:54,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[CAUSES],[CAUSES],due to,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/14/2014 22:58:03,,1323157571,7/14/2014 22:57:17,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],immediate side effect is,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 01:23:46,,1323257598,7/15/2014 01:22:23,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",due to,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 02:49:57,,1323303961,7/15/2014 02:49:21,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],immediate side effect,not applicable,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 04:48:52,,1323353002,7/15/2014 04:47:52,gifthulk,1.0,20382530,CAN,ON,Hamilton,216.209.129.175,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]",common immediate side effect direct central,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 05:20:55,,1323363903,7/15/2014 05:19:45,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],side effect due to direct central EFFECT ON,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 05:26:39,,1323365662,7/15/2014 05:25:26,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SIDE_EFFECT] [SYMPTOM],"[SYMPTOM]
[SIDE_EFFECT]",side effect central EFFECT,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 06:35:40,,1323386310,7/15/2014 06:34:49,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],due to direct central EFFECT,n/a,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007880,7/15/2014 07:32:36,,1323409631,7/15/2014 07:32:17,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],due to direct central,N/A,83,41,118,60,-1,RO-has_definitional_manifestation,904633-FS1,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
503007881,7/14/2014 20:50:17,,1323090913,7/14/2014 20:49:53,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],LYMPH NODE METASTASES METASTATIC LESION,Different symptoms,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 21:08:06,,1323100321,7/14/2014 21:06:48,clixsense,1.0,15189335,GBR,H9,London,188.29.164.19,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the internal mammary chain were,Na,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 21:12:56,,1323102486,7/14/2014 21:12:25,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METASTASES METASTATIC,n/a,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 21:17:36,,1323104598,7/14/2014 21:17:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the lymphoid,N/A,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 21:24:52,,1323107832,7/14/2014 21:24:36,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],were,n/a,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 21:28:14,,1323109661,7/14/2014 21:27:20,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],invasion,n/a,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 21:28:30,,1323109818,7/14/2014 21:28:11,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],in the,N/A,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 22:27:57,,1323145190,7/14/2014 22:27:00,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,[ASSOCIATED_WITH],[ASSOCIATED_WITH],types of lymphatic invasion,N/A,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 22:48:56,,1323153391,7/14/2014 22:47:48,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],types of lymphatic invasion,N/A,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 23:35:26,,1323175653,7/14/2014 23:34:34,neodev,1.0,15825691,CAN,BC,Surrey,96.48.129.199,[SYMPTOM],[SYMPTOM],were LYMPH NODE METASTASES METASTATIC LESION,N/A,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/14/2014 23:44:54,,1323182032,7/14/2014 23:43:51,superrewards,1.0,23067591,USA,VA,Lynchburg,76.104.12.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION",na,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/15/2014 00:43:56,,1323227974,7/15/2014 00:43:33,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],types of lymphatic invasion,different types,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/15/2014 01:54:42,,1323277847,7/15/2014 01:54:16,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Different tests,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/15/2014 02:09:42,,1323286867,7/15/2014 02:08:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LYMPH NODE METASTASES METASTATIC LESION,n/a,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
503007881,7/15/2014 03:15:09,,1323314113,7/15/2014 03:14:11,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],"LYMPH NODE METASTASES in 88 cent, METASTATIC LESION in 29 per cent",N/A,114,76,130,97,-1,RO-disease_has_finding,901920-FS1,"The types of lymphatic invasion observed in the internal mammary chain were LYMPH NODE METASTASES in 88 per cent, METASTATIC LESION in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",METASTATIC LESION,LYMPH NODE METASTASES
